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1. INTRODUCTION 
 
 
 
1.1. Role of cytokines and chemokines in peripheral inflammation and 
neuroinflammation 
Immune and nervous system have evolved to provide regulation of physiological 
homeostasis and to protect against threats (González H. et al., 2014): the role of immune 
system is to defend the organism against infection and injury, whereas, the nervous 
system integrates biological functions and provides a nearly instantaneous 
homeostatic control mechanism by releasing neurotransmitters and other regulatory 
molecules (Chavan S. S. et al., 2017). This cross-talk is suggested by the presence of 
neurotransmitters receptors (such as acetylcholine and adrenergic receptors) on the 
surface of many immune cells (like macrophages, dendritic cells, T cells and others) 
and, in turn, the ability of immune cells to synthesize and release substances classically 
designated as neurotransmitters and neuromodulators (acetylcholine, dopamine and 
other catecholamines) (Rosas-Ballina et al., 2011; Kawashima et al., 2012; Marino and 
Cosentino, 2013). 
To defend the organism from damages, the immune system can launch two types of 
responses:  
• -innate 
• -adaptive 
Innate response includes all defence mechanisms that are encoded in the germline 
genes and are mediated by Pattern Recognition Receptors (PRRs, such as Toll-like 
receptors, TLRs) (Futosi et al., 2013). It acts very quickly, because the recognition 
molecules are already expressed on the surface of many cells. Adaptive immune 
response is characterized by somatic immunoglobulin chains rearrange which allows 
4 
 
a very specific interaction between the target antigen (not only prokaryotic and 
eukaryotic but also viral antigen) and the antigen-specific receptors expressed on the 
surfaces of T and B lymphocytes (Schatz, D. G. et al., 1992). It is slower acting when 
compared to the innate response: initially, it produces a small number of cells able to 
recognize specific antigens that progressively proliferate until a sufficient number to 
conduct an effective immune response is reached. 
Although the innate and adaptive immune systems are described as contrasting 
separate arms of the host response, they usually act together: in both systems many of 
the soluble mediators, which regulate and amplify the immune response, are the same. 
These mediators are proteins and small peptides that could be constitutively present 
in biologic fluids (such as the component of complement system) or released from 
activated immune cells (Medzhitov R., 2007).  
The principal soluble mediators of two responses are cytokines and chemokines: 
cytokines (cyto, from Greek "κύτος" kytos "cavity, cell" plus kines, from Greek 
"κίνηση" kinisi "movement") are a broad category of small proteins (about 5–20 kDa) 
that are important in cell signalling, and chemokines (Greek -kinos, movement) belong 
to cytokines family with interferons (INF) interleukins (IL), lymphokines (L) and 
tumour necrosis factors (TNF); their name is derived from their ability to induce 
directed chemotaxis in nearby responsive cells. Cytokines and chemokines are 
produced by several types of cells (including macrophages, T and B lymphocytes, mast 
cells, endothelial cells and fibroblasts) and they are usually classified by structural 
characteristics; for cytokines: 
1) the four-α-helix bundle family: the members have similar three-dimensional 
structures with four bundles of α-helices. This group is divided in others three 
subfamilies: IL-2 (that includes IL-4, IL-7, IL-9, IL-15, IL-21 erythropoietin and 
thrombopoietin), IFN (that includes IFN-α, IFN-β, IFN-γ, IFN-ε, IFN-κ and IFN-ω) and 
IL-10 (that includes IL-19, IL-20, IL-22, IL-24); 
2) the IL-1 family, which primarily includes IL-1 and IL-18; 
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3) the IL-17 family, which has yet to be completely characterized but it has a key 
role in inducing and mediating of proinflammatory responses, mainly in autoimmune 
diseases; 
4) the cysteine-knot cytokines: include members of the Transforming-Growth-
Factor-beta superfamily, including TGF-β1, TGF-β2 and TGF-β3. 
Also for the chemokines, it is possible to recognize four groups and the classification 
depends on the spacing of their first two cysteine residues: 
1) CXC group (or α-chemokines): from N-terminal sequence, it is possible to 
identify a sequence CXC (Cys-X random amino acid residue-Cys) where one amino 
acid residue separates the two cysteine residues. In mammals, there have been 
described 17 different CXC chemokines, which are subdivided into two categories: 
those with ELR sequence (glutamic acid–leucine–arginine, called ELR-positive 
chemokines) preceding the CXC sequence (chemoattract for neutrophils, such as IL-8) 
and those without an ELR motif (ELR-negative, chemoattract for lymphocytes, like 
CXCL13); 
2) CC group (or β-chemokines): the first two cysteine residues are adjacent to each 
other. Members of this family chemoattract monocytes/macrophages (CCL2 or MCP-
1), basophils, eosinophils and T lymphocytes (CCL5 or RANTES) but have little or no 
effect on neutrophils;  
3) C group (or γ chemokine): containing only two of the four conserved cysteine 
residues and the only members of this family are lymphotactin-α and -β (or XCL1 and 
XCL2), which are known to chemoattract T lymphocytes; 
4) CX3C group (or δ chemokine): the only CX3C chemokine discovered until now 
is called fractalkine (or CX3CL1). It is characterized by the presence of three amino 
acids between the first two cysteine residue. It has double action as chemoattractant 
and adhesion molecule.  
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Chemokines exert their biological effects through cell-surface receptors that belong to 
G protein–coupled receptors (GPCRs) family. There have been characterized 
approximately 19 different receptors and their nomenclature follows that of 
chemokines: CXCRn, CCRn, XCRn and CX3CRn.  
The structure of chemokine receptors is a single polypeptide chains of about 350 
residues spanning 7 times the membrane, three intracellular and three extracellular 
hydrophilic loops, a short amino-terminal (N-terminal) extracellular domain and a 
serine/threonine-rich intracellular carboxyl-terminal (C-terminal) domain, important 
for receptor regulation. In the first two extracellular loops are present 2 of 4 conserved 
cysteine residues that allow the formation of the first disulphide bound required for 
the definition of the molecular structure, whereas, the second one is due to the bound 
between the N-terminal domain and the third extracellular loop structure (Bonecchi et 
al., 2009). Chemokine receptors activate various signalling pathways, such as the 
Mitogen-Activated Protein Kinase (MAPK) pathway, the Phospholipase C (PLC) 
pathway resulting in Ca2+ influx, and the phosphatidyl inositol-3 kinase (PI3K) 
pathway (Bajetto et al., 2002; Cartier et al., 2005), leading to varied functional outcomes, 
including adhesion, polarization and chemotaxis.  
Functionally, chemokines are divided in two groups: homeostatic (such as CCL14, 
CCL19, CCL20, CCL21, CCL25, CCL27, CXCL12 and CXCL13, they are constitutively 
present in certain tissues) and inflammatory (such as CXCL-8, CCL2, CCL3, CCL4, 
CCL5, CCL11, CXCL10) that they are product in response to pro-inflammatory stimuli. 
 
 
1.2. Peripheral inflammation 
Inflammation is a primary host response that is triggered by noxious stimuli and 
conditions, such as pathogens, tissue injury, irritant substances, undegradable foreign 
bodies or cellular debris. In periphery, inflammation is characterized by five cardinal 
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signs: redness (rubor), heat (calor), swelling (tumor), pain (dolor) and loss of function 
(functio laesa) (Gallin et al., 1992).  
Redness and heat are the results of an increase of blood flow, swelling is due to an 
increased vascular permeability, pain occurs through activation and sensitization of 
primary afferent nerve fibres and functio laesa is the result of these alterations. These 
modifications happen following the activation of both immune and peripheral 
nervous system: indeed, they have a common integrate protective function in host 
defence and in the response to tissue injury (Chiu I.M. et al., 2012).  
During the effector phase of inflammation, many cellular changes occur: initially, 
around the site of damage, the vascular blood vessels respond by increasing blood 
flow and enhancing vascular permeability trough vasodilation; the latter is mediated 
by nitric oxide (NO) and vasodilatory substances such as Prostaglandins (PGI2), 
Calcitonin Gene-Related Peptide (CGRP) and Substance P (SP). NO is produced from 
L-arginine through the action of nitric oxide synthase (NOS).  
The purpose of the vasodilation is to make easier the penetration of soluble mediators 
and inflammatory cells. Neutrophils are the first and most abundant leukocytes to be 
recruit to a site of injury or inflammation by chemokines (CXCL8 family, including 
CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8) and their 
transmigration process consists in a series of stages: 
• Margination 
• Rolling 
• Adhesion 
• Extravasation or transmigration  
When neutrophils reach the afflicted tissue site, they become activated (either by direct 
contact with inducer or through the actions of cytokines secreted by tissue-resident 
cells) and try to eliminate the inducer agents by releasing of high potent effector 
contain in their granules (De Oliveira S. et al., 2016; Smolen J. E. et al., 2000; Sharwood 
E.R., 2004).  
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This response does not discriminate between microbial and host targets, thus collateral 
damage to host tissues is unavoidable with cellular debris production. (Nathan C. et al, 
2006). The elimination of the inducer agents is usually followed by a resolution and 
repair phase (Figure 1): production of arachidonic acid metabolites such as Lipoxin A4 
(LXA4) and Lipoxin B4 (LXB4) inhibit the neutrophils recruitment and promote the 
recruitment of monocytes, which remove, together to tissue-resident macrophages, 
dead cells and initiate tissue remodelling (Serhan, C. N. and Savill, J., 2005). The 
initiation of tissue repair is mediated by macrophage products such as resolvins, 
protectins, TGF- β and others growth factors (Medzhitov R., 2008). 
 
 
Figure 1. Cellular interplay during resolution of inflammation. Overview of cellular processes during 
onset (left) and resolution (right) of inflammation. (Ortega-Gómez A et al., 2013). 
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In addition to immune cells, a relevant role is played by primary afferent sensory 
neurons; indeed, they are involved in signals transduction associated with pain 
sensation and are classified in:  
• Aβ-fibres: large-diameter myelinated fibres, involved in conduction of non-
nociceptive input, such as a simple touch, vibration or movement. Following 
persistent nociceptive stimulation, the afferent impulses of Aβ fibres can be 
interpreted as pain (allodynia); 
• Aδ fibres: medium-to-small-diameter, myelinated fibres, respond to mechanical 
and thermal stimuli, involved in the “first pain” response; 
• C fibres: small-diameter, nonmyelinated fibres, involved in responses to 
mechanical, chemical or thermal stimulation; they are responsible for “second 
pain”, because respond to nociceptive stimulation only when they become 
sensitized, such as following inflammation. 
During inflammation, the release of cytokines and chemokines by immune cells or the 
activation of danger signal receptors (such as Transient Receptor Potential cation 
channels, TRPV1, TRPM8, and TRPA1) on the surface of afferent neurons can activate 
signalling mechanisms that increase their membrane excitability (Figure 2).  
For instance, excitations of C fibres result in the generation of action potentials conduct 
not only orthodromically to the central nervous system (CNS) but also antidromically 
into inactive branches of the afferent fibre, inducing release of soluble mediators such 
as cytokines, chemokines, SP, CGRP and neuropeptide Y.  
These molecules rapidly activate various cell types, including immune and endothelial 
cells with consequent increase of vascular permeability, vasodilation and protein 
extravasation. The entire process may be self-amplifying, because cytokines, 
chemokines and neuropeptides can operate both in autocrine or paracrine fashion in 
primary sensory neurons and lower their threshold for further neurotransmitter and 
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neuropeptide release, process called “sensitization” (Xanthos D.N. and Sandkühler J., 
2014; Chiu I. M. et al., 2012). 
 
Figure 2. Noxious stimuli, microbial and inflammatory recognition pathways trigger activation of 
the peripheral nervous system. Sensory neurons possess several means of detecting the presence of 
noxious or harmful stimuli. (1) Cytokine receptors recognize factors secreted by immune cells, which 
activate MAP kinases and other signalling mechanisms to increase membrane excitability. (2) Danger 
signal receptors, including TRP channels, recognize exogenous signals from the environment (for 
example, heat, acidity, chemicals) or endogenous danger signals released during trauma or tissue injury. 
(3) Pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), recognize pathogen-
associated molecular patterns (PAMPs) released by invading bacteria or viruses during infection (Chiu 
I. M. et al., 2012). 
 
 
1.2.1. Peripheral inflammation: Inflammatory Bowel Diseases (IBDs) overview 
Peripheral inflammation, in addition to its role in host defence, contributes to the 
pathophysiology of many chronic diseases. For instance, inflammatory bowel diseases 
(IBDs), is a group of inflammatory conditions of the colon and small intestine 
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characterized by chronic relapsing intestinal inflammation. Crohn’s disease and 
ulcerative colitis are the two majors form of IBDs. Their incidence is increased over the 
years (Molodecky, N. A. et al. 2012) and, for this reason, they represent a big issue for 
the worldwide health-care (Lakatos P.L., 2006). Although their aetiology remains 
largely unknown, as reporter by Fiocchi, the onset of these disease is linked to a 
complex interaction between the genetic, environmental, microbial factors and the 
immune responses (Fiocchi C., 2015).  
A combination of these IBDs risk factors seems to initiate alterations in epithelial 
barrier function thereby allowing the translocation of luminal antigens (for example, 
bacterial antigens from the commensal microbiota) into the bowel wall. Subsequently, 
the aberrant and excessive activation of mucosal immune cells, such as macrophages 
and T cells, induced cytokine/chemokine release that give rise to a subclinical or acute 
inflammatory state (Strober W. et al., 2002). In particular, many studies conducted both 
in human and in rodents reported an increase expression of pro-inflammatory 
cytokines IL-1β and TNF-α (Reinecker H. C. et al, 1993; Antoniou E. et al., 2016; Derrick 
D. E. and Kusum K. K., 2017). 
Interestingly, a therapy with biologic agents (such as Infliximab or Adalimumab) is 
currently used in therapy to block the action of TNF-α (Swoger J. M. et al., 2010; Billiet 
T. et al., 2013; Peng J. C. et al., 2014). This confirm that pro-inflammatory cytokines exert 
a key role in the development of IBDs. However, an inflammatory response is 
characterized by an ongoing infiltration of circulating immune cells.  
This cell-trafficking is regulated by chemokines and several studies showed an 
increased colonic expression of CXCR1 and CXCR2 (the receptors of CXCL8) both in 
animal models of colitis (Buanne, P. et al., 2007; Bento et al., 2008) and in biopsy tissues 
from mucosa of IBD patients (Mazzucchelli et al., 1994; Puleston et al., 2005). Moreover, 
CCL5 (RANTES) that is able to attract CCR1 and CCR5 expressing cells into the 
mucosa (Kunkel E.J. et al., 2002; Oki M. et al., 2005) is increased in the peripheral 
monocytes of Crohn’s disease patients (Schwarzmaier D. et al., 2013). At the same way, 
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several studies identified elevated CCL2 mRNA and protein expression in the colon 
of IBDs patients (Aomatsu T. et al., 2012).  
Although the studies reported above prove the involvement of cytokines and 
chemokines in the development of IBDs, our knowledge is still far from the 
understandings of the complete mechanism of diseases development. 
 
 
1.3. Neuroinflammation 
For decades, the brain has been viewed as an “immune-privileged” organ, where 
inflammation can only occur through direct infection or after the breakdown of the 
blood–brain barrier (BBB) and subsequent infiltration of peripheral immune cells. 
Recent studies have demonstrated how this concept is not completely exact and the 
new term “neuroinflammation” was born. As suggested by the name, it indicates a 
process that involve nervous tissue: indeed, it is characterised by activation of 
microglial cells, astrocytes, neurons and endothelial cells, consequent changes in the 
permeability of the BBB followed by the infiltration of peripheral immune cells into 
the CNS parenchyma, secretion of inflammatory cytokines and chemokines and, 
finally, neuronal damage and death (González H. et al., 2014).  
Several studies strongly suggest that neuroinflammation is a pivotal process involved 
in the progression of many neurodegenerative diseases, such as Parkinson’s disease 
(De Virgilio A. et al., 2016; Vivekanantham S. 2015), psychiatric disorders (Na KS. Et al., 
2014; Jones K.A. and Thomsen C., 2013), mood disorders (Hurley L.L. and Tizabi Y. 2013; 
Young J. et al., 2014), multiple sclerosis (MS) (Naegele M. and Martin R., 2014) or 
Alzheimer’s disease (Heneka M.T. et al., 2015; Pimplikar S.W., 2014; Heppner F.L., 2015; 
Liu C. et al., 2014).  
During neuroinflammation, three mainly events occur: 
• synaptic impairment: is one hallmark of neurodegenerative disorders and of 
the early progression of dementia (Masliah et al., 2001). It is manifested through 
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loss of synaptic function and impairment of synaptic plasticity, resulting in 
alteration of memory formation and consolidation: indeed, neurons are 
damaged and inadequate for neurotransmission and astrocytes are not able to 
preserve the synaptic homeostasis (Faissner et al., 2010); 
• inhibition of neurogenesis: in adults occurs in subgranular layer (SGZ) of the 
dentate gyrus (DG) in the hippocampus as well as other areas such as the 
subventricular zone of the lateral ventricles and the amygdala (Bernier et al., 
2002). Studies showing an age-related decline in hippocampal neurogenesis 
suggest that it may contribute to the cognitive deficits observed in the early and 
later stages of neurodegenerative diseases, particularly in dementia (Kuhn et al., 
1996). During neuroinflammation, neurogenesis is a negatively modulated 
process: indeed, pro-inflammatory cytokines such as IL-6, TNF-α and IL-18 (Liu 
et al., 2005) and microglia activation by Toll-like receptors (TLRs) can inhibit 
neurogenesis (Rolls A. et al., 2007); 
• neuronal death: may be necrotic or apoptotic. During neuroinflammation, 
many pro-apoptotic pathways are activated which can accelerate long-term 
neurodegeneration (Lyman M. et al., 2014). In addition to cytokines, nitric oxide 
(NO) also plays a key role in this process: NO synthesis can be increased by the 
enzyme inducible Nitric Oxide Synthase (iNOS) from astrocytes and microglia, 
NO causes apoptosis by inhibiting neuronal respiration, which increases 
glutamate release, resulting in NMDA receptor-mediated excitotoxic cell death 
(Bal-Price A. and Brown G. C., 2001). 
The main cellular actors in neuroinflammation are neurons, microglia and astrocytes. 
Neurons are about 100 billion and represent the chief type of cell in the brain. 
Traditionally, were believed to be passive viewers in neuroinflammation, whereas, 
more recent studies suggest that neurons themselves can produce inflammatory 
mediators such as COX-2-derived prostanoids (Davis S. and Laroche S., 2003), cytokines 
such as IL-1β, IL-6, and TNF-α (Gong C. et al., 1998; Murphy P. G. et al., 1999) and 
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inflammatory induced enzyme iNOS (Heneka M. T. et al., 2001). However, as 
mentioned above, also microglia and astrocytes contribute in the onset and 
progression of AD.  
Microglia is a cellular population of brain with myeloid origin and, in physiological 
condition, represent about 10-15% of all cells of Central Nervous System (CNS). 
Depending on their localization, they acquire a compact or ramified phenotype. The 
latter, thanks to the high number of process, can facilitate the interaction between 
neighbouring blood vessels, neurons and astrocytes (Wake H. et al., 2009) an important 
process for cerebral tissue maintenance (Paolicelli R. C. et al., 2011) and neuronal 
plasticity (Parkhurst C. N. et al., 2013).  
Depending on the integration of regulatory signals, microglial activation seems to be 
a highly regulated process (although is not yet fully understood); however, microglia 
may undergo to distinct kinds of activation:  
• M1-like phenotype: neurotoxic phenotype, similar to peripheral macrophages 
that generate a detrimental microenvironment for neurons by producing 
inflammatory cytokines and Reactive Oxygen Species (ROS); 
• M2-like phenotype: a neuroprotective phenotype that secrete neurotrophic 
factors and anti-inflammatory mediators, thus inducing a supportive 
microenvironment for neurons (Kettenmann H. et al., 2011). 
After CNS injury or infection, there is an initial inflammatory response mediated by 
M1-like microglia: this early activation plays a beneficial role, involving microbicide 
and phagocytic activity of cellular debris, which is a necessary condition for reparation 
of lesions. At the same time, M2-like microglia participate in attenuating inflammation 
induced by M1-like microglia and produce neurotrophic factors, thus promoting tissue 
reparation (Shechter, R. et al., 2013). If M1-like microglia undergo to over-activation, 
inflammation can become a chronic condition which results in the production of 
cytokines, chemokines and neurotoxic factors that can lead to neuronal loss over time 
(Burguillos M. A. et al., 2011). 
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For the brain homeostasis, astrocytes play a key role (Figure 3): they represent about 
20-40% of all glia cells but the precise proportion depends from the different cerebral 
areas (Verkhratsky A. and Butt A. M., 2013). 
 
 
Figure 3. Astrocytes as central homeostatic elements in CNS. Astrocytes represent a highly 
heterogeneous cell population, they provide structural support for other cellular elements of the CNS 
and control homeostasis and turnover of several key neurotransmitters and neuromodulators 
(Verkhratsky A. et al., 2014). 
 
As well as remember their name, astrocytes have a characteristic star-shape and they 
perform many functions: biochemical support of endothelial cells that form blood–
brain barrier (BBB), maintenance of ion balance and regulate pH of microenvironment, 
contribute to synaptogenesis, modulate information processing and signal 
transmission, regulate neural and synaptic plasticity, supply of nutrients, maintain 
excitability and connectivity of neuronal network (Zlokovic B. V. 2008; Iadecola C. and 
Nedergaard M. 2007; Walz W., 2000; Deitmer J. W. and Rose C. R.,1996; Perea G. et al., 2009; 
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Sofroniew M. V. 2014). In case of injury, astrocytes quickly change in activate phenotype 
increasing GFAP and neurotrophic factor S100β production (Mrak R. E. and Griffin 
W.S., 2001a and 2001b). 
 
 
1.3.1. Neuroinflammation: Alzheimer’s Disease (AD) overview 
At beginning of last century, the psychiatrist Alois Alzheimer presented a clinic 
pathological case of dementia in a fifty-years old woman, named Auguste D. He 
followed her case until she died and, in the 1906, he reported publicly on it (Alzheimer 
A., 1907). During the next years, other scientists reported similar cases in the medical 
literature and some of them used the term “Alzheimer's disease” (AD), name still now 
used (Berchtold N. C. and. Cotman C. W., 1998). AD is a chronic progressive 
neurodegenerative disorder characterised by three primary groups of symptoms:  
• cognitive dysfunction (memory loss, language difficulties and executive 
dysfunction);  
• psychiatric symptoms and behavioural disturbances (depression, 
hallucinations, delusions, agitation); 
• comprises difficulties with performing activities of daily living (driving, 
shopping, and managing self-care) (Burns A. and Lliffe S., 2009). 
The cause of AD is not yet understood but the onset is associated with neuronal death 
resulting by neuroinflammation. The pathological hallmarks of the disease are:  
1. alterations in the production or clearance of amyloid beta (Aβ) peptides: Aβ 
peptides derive from the amyloid precursor protein (APP). APP is cleaved by 
α, β and γ secretase that are involved in non-amyloidogenic and amyloidogenic 
pathway. In the non-amyloidogenic pathway, α-secretase cleaves APP 
generating a soluble fragment of APP and a membrane-bound carboxyl-
terminal fragment; whereas, in the amyloidogenic pathway (Figure 4), β- and 
17 
 
γ-secretase (or β-site APP cleaving enzyme, BACE-1) cleave APP in fragments 
of 30-51 amino acid residues (Mu Y. and Gage F. H., 2011). The most common 
peptides are Aβ1-40 and Aβ1-42 that have fibrillogenic activity and can aggregate 
into insoluble oligomeric form that leads production of extracellular Aβ plaques 
(Hamley I. W., 2012); 
 
 
Figure 4. Amyloid β-protein generation by normal proteolytic processing of β-amyloid precursor 
protein (APP). In the amyloidogenic processing of APP are involved β-site APP-cleaving enzyme 
(BACE) and the γ-secretase complex. Full-length APP is first processed by BACE, and the large 
ectodomain is secreted, whereas, the remaining peptide (CTFβ) binds to a docking site on the surface of 
the γ-secretase complex and then, transferred to the active site that includes transmembrane domains 6 
and 7 of presenilin-1 (PS1) or PS2. Subsequently, PS1 and PS2 are both activated by presumed 
autoproteolytic cleavages, which create their N-, and C-terminal fragments (NTF and CTF). These bind 
to each other and also to 3 other essential γ-secretase components, APH1a (or APH1b), PEN2 and 
nicastrin (NCT) forming the core complex required for γ-secretase activity. The γ-secretase cleavage 
occurs in the middle of the membrane and liberates amyloid β-protein (Aβ). In the frame, are 
highlighted various proposed sites of intramembrane proteolysis by γ-secretase (Haass C. and Selkoe D. 
J., 2007). 
 
2. hyperphosphorylation of Tau protein (a microtubule-associated protein) that 
provokes intracellular neurofibrillary tangle (NFT) formation (Haass C. and 
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Selkoe D. J., 2007). Although NFT may better correlate with the decline in 
cognitive skills in AD, it looks to be a downstream event of Aβ accumulation 
(Figure 5), however, some experimental evidences indicate that Aβ plaques 
have direct toxic effects and may promote neurodegeneration by the activation 
of microglial cells and astrocytes (Regen F. et al., 2017; Heneka M. T et al., 2015). 
 
 
Figure 5. The amyloid β-protein (Aβ) cascade (Haass C. and Selkoe D. J., 2007). 
 
Many years ago, it was demonstrated that amyloid peptides and their precursor 
protein APP are potent glial activators (Barger S. W. and Harmon A. D., 1997): indeed, 
trough TLR4, aggregated amyloid-β (Aβ) stimulates microglial cells to produce strong 
levels of pro-inflammatory factors such as NO, IL-6 and TNF-α (Walter S. et al., 2007) 
and TLR4 polymorphism has been associated with elevated risk of AD (Balistreri C. R. 
et al., 2009). Astrocytes have a controversial role for Aβ clearance and degradation: 
indeed, astrogliosis occurs in AD, probably because astrocytes can form a protective 
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barrier between Aβ deposits and neurons but, in response to chronic stress (such as 
pro-inflammatory cytokines) they could overexpress BACE1 enzyme becoming a 
source of Aβ themselves (Roßner S.et al., 2005). Nevertheless, several studies underline 
the role of chemokines in AD: for example, increased levels of CXCL8 have been 
detected in patients with AD (S. Franciosi, et al., 2005) as well as augmented expression 
of CCL5 in astrocytes which has modulatory effect on microglia activation (Skuljec J. et 
al., 2011) but its role in AD is still controversial (Tripathy D. et al., 2010). Moreover, 
CCL2 induces activation of astrocytes influencing Aβ peptide accumulation and 
production of proinflammatory cytokines and chemokines causing neuronal death 
(Lee Y. K. et al, 2009).  
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2. Bv8 AND PROKINETICIN SYSTEM:  
A NEW FAMILY OF CHEMOKINES 
 
 
 
About twenty years ago, for the first time by our research group, a small peptide of 77 
amino acid was isolated from skin secretions of Bombina variegata frog and called Bv8, 
to indicate its origin and molecular mass of 8 KDa. Its homologues were founded in 
spiders (atracotoxin-Hvf17), snakes (Mamba Intestinal Toxin-1, MIT1) rodents and 
humans (PK1 or Endocrine Gland-derived Vascular Endothelial Grow Factor, EG-
VEGF and mammalian Bv8 or PK2). Zhou and colleagues, termed the corresponding 
proteins “prokineticin 1” (PK1) and “prokineticin 2” (PK2) again mainly referring to 
their ability to contract guinea pig ileum in vitro, a property shared by this group of 
proteins (Mollay C. et al., 1999; Negri L. et al. 2002; Kaser A. et al., 2003). The amino acid 
sequence of Bv8 is similar to MIT-1: indeed, they have 58% of sequence identity (Negri 
L. et al., 2002). Furthermore, PK1 have an overall identity of 58% and homology of 76% 
with human PK2 and murine Bv8 and 43% identity with amphibian Bv8 (Masuda Y. et 
al., 2002). These proteins have some commons structural characteristics (Figure 6): 
• identical amino-terminal (N-terminal) sequence important for the biological 
activity and receptor recognition (alanine, valine, isoleucine, threonine, glycine 
and alanine, AVITGA sequence), for this reason, they are also named ‘AVIT 
proteins’ (Bullock C. M. et al., 2004; Negri L. et al., 2005; Kaser A. et al. 2003); 
• 10 cysteine residues with identical spacing that define a five disulphide bridges, 
motif called a colipase fold, that confer to the molecule a compact three-
dimensional conformation and high protection from enzymatic degradation 
(Kaser A. et al., 2003); 
• tryptophan (W) residue in position 24, very important for receptor binding. 
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Figure 6. Amino acid sequences of human and mouse PKs and their homologues from frog and 
snake. AVITGA - dark blue; cysteine (C) - red; tryptophan (W) - light blue. 
 
PK1 and PK2 share only 44% amino acid identity and most of this homology resides 
in the N-terminal signal peptide and the distinct AVITGA sequence motifs that are 
highly preserved across species (fish, frog, snake, and various mammalian species) (Li 
M. et al., 2001; Kaser A. et al., 2003). As mentioned above, the AVITGA sequence is 
implicated in receptor recognition and the high degree of disulphide cross-linking 
gives rise to a remarkably stable compact protein that is highly resistant to protease 
degradation (Bullock C. M. et al., 2004; Boisbouvier J. et al., 1998). Both proteins fold into 
a polarized ellipsoid structure with one side containing a net positive charge and the 
opposite with hydrophobic residues (Protein Data Bank, accession number 1IMT). The 
C- and N- terminal ends are exposed on the surface, whereas the more charged 
residues are buried inside the molecule (Boisbouvier J. et al., 1998). The gene that 
encodes PK1 is located on murine chromosome 3 and human chromosome 1p21. It is 
composed from three exons encoding a precursor protein of 105 amino acids and a 
mature form of 86 amino acids, with no known alternative splicing product (LeCouter 
J. et al., 2003a; Li M. et al., 2001). The pk2 gene maps to murine chromosome 6 and 
human chromosome 3p21.1 and it is composed of four exons (Figure 7), which give 
rise to two mature proteins: PK2 (81 amino acids, exons 1, 2 and 4) and a splice variant 
with a 21-amino acid insert called long PK2 (PK2L, 102 amino acids, exons 1, 2, 3 and 
4) (Jilek A. et al., 2000). The secreted PK2L, contains the additional 21 basic amino acids 
between Lys-47 and Val-48 of the mature PK2 protein and it is supposed to be 
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processed, by furin proteolytic cleavage into a smaller peptide called PK2β, but the 
role of PK2L and PK2β has not yet been elucidated. 
 
 
Figure 7. PK2 and its splice variant PK2L. Gene structure of PK2 and the differential exon use by PK2 
and PK2L mRNA. In red is showed PK2β peptide, the product of PK2L proteolytic cleavage.  
 
The structural elements essential for the function of PKs have been also investigated 
by deletion, insertion, and substitution mutations (Bullock C. M. et al., 2004), as well as 
proteolytic fragmentation (Negri L. et al., 2005). Any disruption of the N-terminal 
hexapeptide sequence renders human PK1 inactive (Bullock C. M. et al., 2004), whereas 
deletion of the N-terminal alanine residue of frog Bv8 results in significant but not 
complete loss of biological activity (Negri L. et al., 2005).  
The amount of data obtained in these first 20 years of research has allowed to classify 
Prokineticins belong to chemokines class, despite that a phylogenetic study (a method 
that analyses the evolutionary relationships between proteins family and their 
members) revealed higher similarity between defensins and Prokineticins than with 
chemokines. Usually, proteins are classified as chemokines according to common 
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structural characteristics, biological functions and kind of receptors that they bound to 
exert their biological effects. These characteristics fit in very well with Prokineticins: 
indeed, together with chemokines, Prokineticins are small secreted peptides (8-10 
KDa), are highly basic proteins and bind sulphate proteoglycans, they both contain 
cysteine residues and they are potent chemoattractant (Monnier J. and Samson M., 2008). 
 
 
2.1. Bv8/Prokineticin receptors 
Prokineticins exert their biological functions through activation of two closely related 
G-Protein Couple Receptors (GPCRs), called Prokineticin Receptor 1, PKR1, and 
Prokineticin Receptor 2, PKR2 (Lin D. C. H. et al., 2002; Masuda Y. et al., 2002; Soga T. et 
al., 2002).  
PKR1 and PKR2 belong to the Neuropeptide Y (NPY) receptor class, have an overall 
identity in their amino acid sequences of 85%, diverge mainly at the N-terminal and 
are about 80% identical to the previously described mouse orphan receptor gpr73 
(Parker R. et al., 2000). They are located on 2p13.1 and 20p12.3 human chromosomes 
for PKR1 and PKR2 respectively. 
In cultured cells that express PKR1 or PKR2 exogenously, data obtained from binding 
experiments show that the non-mammalian peptides Bv8 and MIT display an affinity 
for PKRs at least one order of magnitude higher than that of PK2 and two orders of 
magnitude higher than that of PK1. Except MIT, a clearly PKR2-preferring ligand, all 
the other natural PKs show no selectivity for either receptors (Negri L. et al., 2009). 
Nevertheless, Chen and co-workers showed that, in PKR1- and PKR2-expressing cells, 
unlike PK1 and PK2, PK2β showed high affinity for PKR1 and very low affinity for 
PKR2 (Chen J. et al., 2005). 
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Displacing 
Ligand 
Radioligand (pM) PKR1 (Ki, nM) PKR2 (Ki, nM) 
Bv8 
125I-Bv8,      10 
125I-MIT,      4 
0.34 
0.69 
0.78 
0.71 
MIT 
125I-MIT,      100 
125I-MIT,      1.9 
4.1 
- 
0.67 
0.003 
PK1 
125I-MIT,      100 
125I-PK1,      2000 
250.0 
104.0 
81.0 
34.0 
PK2 
125I-MIT,      100 
125I-PK2,      100 
6.9 
4.5 
7.6 
6.4 
PK2β 125I-PK2,      100 34.6 >1000 
Table 1. Binding affinity of Bv8/PK proteins to PKR1 and PKR2. Data obtained from binding 
experiments using Chinese hamster ovary (CHO) cultured cells that express PKR1 or PKR2 
exogenously.  
 
Several studies show that PKR1 and PKR2 are associated with Gαq, Gαi and Gαs 
proteins and, as consequence of this redundancy, Prokineticins signalling depends on 
tissues-specific expression of the ligands, receptors and associated G proteins and 
which possible signalling pair is involved in specific physiological or behavioural 
process (Figure 8). Indeed, in PKRs transfected neuronal and specific endothelial cell 
lines, the activation of PKRs stimulates intracellular calcium mobilization through 
several mechanisms. One of them is via Gαq coupling that activates Phospholipase C 
(PLC)-β and subsequent formation of inositol 1,4,5-trisphosphate (Lin D. C. H. et al., 
2002b) and calcium release from intracellular stores. Intracellular calcium stimulation 
by PK1 also activates the calcineurin pathway, which induces dephosphorylation of 
the transcription factor, NFAT (Nuclear Factor of Activated T cells), followed by 
nuclear translocation and regulation of gene transcription (Cook I. H. et al., 2010). 
Whereas the stimulation of calcium mobilization upon receptor activation is 
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dependent on Gαq, activation of the MAPK (Mitogen-Activated Protein Kinase) 
pathway is pertussis toxin–sensitive, proving that PKRs may also couple to Gαi 
protein. The coupling of PKRs with Gαi proteins can lead also to ERK (extracellular-
signal-regulated kinase) phosphorylation (Lin D. C. H. et al., 2002b). It has been 
demonstrated that in the Dorsal Root Ganglia (DRG), prokineticin receptors increase 
[Ca2+]i by activation of the TRPV1 channels in a dose-dependent fashion and are 
followed by subsequent translocation of PKC to the neuronal membrane (Vellani V. et 
al., 2006). Cross-talk between the glial cell line-derived neurotrophic factor 
(GDNF)/Ret, transient receptor potential vanilloid 1 (TRPV1) and prokineticin 
signalling have also been reported (Hu W. P. et al., 2006; Ngan E. S. et al., 2008). 
 
Figure 8. Prokineticin Signalling. PK1 and PK2 bind two G-protein coupled receptors (PKR1 and 
PKR2) which are coupling to Gαi, Gαs, Gαq to activate MAPK/Akt, cAMP accumulation and calcium 
mobilization, respectively (Ngan E. S. W. and Tam P.K., 2008). 
 
2.2. Prokineticin receptor antagonists 
As mentioned before, in all members of the Bv8/PK family, the highly conserved N-
terminal sequence AVITGA and the Tryptophan (Trp or W) residue in position 24 are 
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necessary for biological activity (Bullock et al., 2004; Negri et al., 2005); indeed, AVITGA 
family members can interact with PKR1/PKR2 by orienting the protein region that 
comprises the AVITGA sequence and the conserved Trp residue in position 24 (Miele 
R. et al., 2010).  
Deletions and/or substitutions in these conserved residues produces peptides that act 
like antagonist molecules: to give some instances, the N-terminal deletion of the first 
two amino acids in amphibian Bv8 molecule (dAV-Bv8), yields an analogue lacking 
any biological activity but still able to bind the receptors, or the substitution of Trp 
with Ala in position 24, yields a molecule, Ala-24, that preferentially binds and 
activates PKR2 (Negri L. et al., 2005; Lattanzi R. et al., 2012). Despite peptides represent 
an excellent starting point for the design of novel therapeutics, they have some 
weaknesses, such as chemically and physically instability, prone to proteolytic 
hydrolysis, short half-life and fast elimination (Fosgerau K. and Hoffmann T., 2015), 
therefore, Balboni and colleagues have synthesized and developed several 
nonpeptidic prokineticin antagonists (Balboni G. et al., 2008; Lattanzi R. et al., 2014). PC1 
(Figure 9), the lead compound, is characterized by a triazinic group which contain the 
following substitutions: N1 and N5 link a 4-ethylbenzyl and a 4-methoxybenzyl, 
respectively; C2 links an amino-ethyl-guanidine. 
 
 
Figure 9. PC1, chemical structure. 
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PC1 mimics the structural features required for Bv8 receptor binding: indeed, the 
triazine-guanidine moiety of PC1 mimics the N-terminal AVIT sequence, whereas the 
methoxybenzyl moiety is oriented as the Trp residue in position 24 (Balboni G. et al., 
2008). PC1 acts as a preferentially PKR1 ligand as demonstrated by in vitro and in vivo 
experiments conducted in our laboratory. In vitro binding experiments demonstrated 
that PC1 has 30 times higher affinity for PKR1 (IC50 = 104 nM) than for PKR2 (IC50=3200 
nM) and it behaves as an antagonist because it blocks the Bv8-induced [Ca2+]i 
mobilization in G-protein coupling PKR1- and PKR2-transfected CHO (Chinese 
Hamster Ovary) cells (Balboni G. et al., 2008). Another analogue of PC1 has been 
synthesized: the 4-ethylbenzyl group in position 5 of PC1 structure was replaced with 
a 4-fluorine atom to give PC7 (Figure 10). In vitro assays show that PC7 results about 
100 times more selective for PKR1 than for PKR2 (IC50 = 36 nM IC50 = 4400 nM, 
respectively) and displays 4 times higher affinity for PKR1 than the lead compound 
PC1 (Lattanzi R. et al., 2014). 
 
 
Figure 10. Affinity and selectivity of PC1 and PC7 expressed as IC50 values. The affinity and 
selectivity of PC1 and PC7 was evaluate in vitro, using the BRET (Bioluminescence Resonance Energy 
Transfer) technology in neuroblastoma SHSY5Y cells expressing luminescent PKR1 or PKR2 and 
fluorescent Gβ1 subunit (Lattanzi R. et al., 2014). 
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2.3. Distribution and functions of Prokineticins and their receptors 
Several studies show that both prokineticin receptors are distributed throughout the 
body: PKR1 is mainly expressed in peripheral tissues, including endocrine glands and 
organs of the reproductive system, spleen, gastrointestinal tract, lungs, heart and 
immune cells (such as neutrophils and macrophages) whereas, in the central nervous 
system (CNS), PKR2 is more abundantly expressed and PKR1 is present only in 
discrete brain areas (Soga T. et al., 2002; Lin D. C. et al., 2002; Cheng M. Y. et al., 2006; 
Negri L. et al., 2007).  
Distinct expression patterns have been reported in various tissues, which provide the 
clue for their tissue-specific biological functions. In addition, differential G-protein 
expression pattern and multiple G-protein coupling of the receptors further increase 
the functional complexity of the system, allowing cells to perform different 
physiological functions, in response to the same ligand stimulation. 
The name “Prokineticins” was assigned to PK1 and PK2 by Zhou and colleagues (Li 
M. et al., 2001) and reflects their ability to induce specific and potent contractions on 
the smooth muscle of the gastrointestinal tract. Subsequently, other functions are 
identified. As far as the reproductive system is concerned, PK1 is predominantly 
expressed in steroidogenic tissues, including the ovary, uterus, placenta and adrenals 
in response to the hormonal changes across the menstrual cycle and during pregnancy; 
whereas, PK2 is mainly (but not exclusively) expressed in non-steroidogenic cells of 
the testis, is undetectable in human ovary and in the endometrium its expression 
remains constant across the menstrual cycle (Maldonado-Perez D. et al., 2007; Ngan E. S. 
et al., 2006; Denison et al., 2008).  
The PKs/PKRs are expressed in the endothelial cells of vascular tissues. PK1 and PK2 
both exert vascular effects through activation of PKRs and, more specifically, PKR1 
activation acts to enhance cell proliferation and survival; whereas, PKR2 is implicated 
in regulating of endothelial cell permeability (LeCouter J. et al., 2003a; Lin D. C. et al., 
2002; Kisliouk T. et al., 2003). PKR1 is also strongly expressed in endothelial cells of 
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arterioles and vessels and signalling through Gαq11, it induces formation of vessel-
like structures by human aortic endothelial cells; whereas PKR2 is the only 
prokineticin receptor expressed by hepatic sinusoidal endothelial cells (Guilini et al., 
2010). In the disease state, PK1 is highly expressed in many kinds of cancers and is 
thought to be partly responsible for neoplastic angiogenesis (Pasquali et al, 2006; 
Monnier J. and Samson M., 2010).  
In 2004, LeCouter and co-worker.  reported the expression of PK2 as well as of PKR1 
and PKR2 in multiple cell lineages from the bone marrow, while PK1 is undetectable. 
PK2 is able to promote differentiation, survival and mobilization of granulocytic and 
monocytic lineages and both PK1 and PK2 can induce formation of granulocytic and 
monocytic colonies in human and mouse hematopoietic stem cells (LeCoulter J. et al., 
2004).  
In the gut, PKR1 is more abundantly expressed than PKR2: PKR1 is localized in 
epithelial cells, in submucosal and myenteric neurons of ileum and colon (Wade P. R. 
et al., 2010). PK2 is expressed in normal liver, but only in Kupffer cells, the liver resident 
macrophages (Monnier J. et al., 2008). In the mouse embryonic gut, a key role is carry 
out by PK1: is expressed in the mucosa and mesenchyme and is able to modulate 
proliferation and differentiation of enteric neural crest cells (Ngan E. S. et al., 2008).  
As mentioned above, in the CNS, PKR2 is the receptor more abundantly expressed and 
PK2 acts as an endogenous neurotrophic factor to support neuronal survival (Cheng 
M. Y. et al., 2002). Primary cultured neurons, astrocytes and microglia, prepared from 
cerebrum of mouse, indicate that neurons express PKR2 and PK1, whereas cultured 
astrocytes and microglia express PKR1 e PK2 (Koyama Y. et al., 2006). PK1 is also 
express in the brainstem, with high abundance in the nucleus tractus solitarius (Cheng et 
al., 2006). PK2 and PKR2 are also abundantly localize in suprachiasmatic nucleus 
where they control the behavioural circadian rhythm (Cheng et al., 2002). In the 
olfactory bulbs (OBs) PK2/PKR2 signalling plays a key role in the neurogenesis: 
indeed, PK2 works as a chemoattractant for neuronal progenitors derived from the 
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subventricular zone (SVZ) and regulates OBs morphogenesis; PK2- or PKR2-null mice 
display a marked reduction in the size of the OBs, a loss of normal OBs architecture, 
and an accumulation of neuronal progenitors in the rostral migratory stream 
(Matsumoto et al., 2006; Ng et al., 2005).  
 
 
2.4. Prokineticin and pain perception 
During the first years after Prokineticins discovery, several evidences showed their 
involvement in nociception and pain transmission. Indeed, both PKR1 and PKR2 are 
localized in the main stations of pain pathway, such as in peripheral terminals of 
nociceptor axons, in the Dorsal Root Ganglia (DRG), in outer layers of the dorsal horns 
of the spinal cord and at the supraspinal level in the Peri-Aqueductal Grey (PAG) and 
Rostral Ventromedial Medulla (RVM) nuclei (Negri L. et al., 2006; deNovellis V. et al., 
2007). In particular, systemic Bv8 injection shows a biphasic time-course: an initial 
rapid phase of hyperalgesia peaks after 1 hour and is followed by a secondary phase 
peaking at 4-5 hours. The initial phase of hyperalgesia is due at least in part to a local 
action on nociceptors, whereas, the second phase is due to release of neuropeptides 
implicated in pain processing, such as Calcitonine Gene Related Peptide (CGRP) and 
substance P in the spinal cord (De Felice et al., 2012).  
The increase in nociceptor excitability results from functional interaction between 
PKR1 and TRPV1, two co-expressing receptors in the DRG. A previous study 
conducted from our group demonstrate that in primary cultures of DRG neurons, 
about 70% of TRPV1 expressing neurons co-express PKR1, whereas a smaller 
proportion (~9.5%) co-express PKR2. Other evidences of PK system involvement in 
pain perception are given by mice lacking PKR1, PKR2 or PK2 gene that exhibit 
impaired pain perception to various stimuli (thermal, mechanical, and capsaicin) 
(Negri L. et al., 2006; Hu W. P. et al., 2006). In the central nervous system, the Bv8 intra-
PAG administration exerts a pro-nociceptive action by increasing the intrinsic GABA-
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ergic tone which, in turn, is responsible for the inhibition of PAG antinociceptive 
output neurons impinging on RVM neurons (deNovellis V. et al., 2007).  
Previous studies conducted in rodents by our group highlight a critical role for PK2 in 
granulocyte-mediated inflammatory pain. In animal model of inflammatory pain 
induced by injection of complete Freund’s adjuvant (CFA) in the hind paw, there is a 
strong activation of the PK system: PK2 expression forcefully increase in mouse and 
rat hind paw skin and this increase is PKR1-mediated.  
Moreover, PKR1 is the mainly receptor involved in hyperalgesia (Negri L. et al., 2006) 
and the PK2 increase in the inflamed paw correlates with the development and 
duration of pain. Interestingly, the inflammatory pain response has higher intensity 
and longer duration in rats than in mice and this effect is probably due to the larger 
expression of PK2L, (the splice variant of PK2) (Giannini E. et al., 2009). PK2L is 
susceptible to proteolytic cleavage that give rise to a small peptide called PK2β that 
selective binds PKR1 (Chen J. et al., 2005). 
PK system is involved in chronic pain conditions, such as neuropathic pain. Indeed, it 
is a pain caused by damage or disease affecting the somatosensory nervous system 
and its development and maintenance involves interactions between neurons, 
inflammatory immune cells, glial cells, as well as a wide cascade of cytokines and 
chemokines (Austin P. J. and Moalem-Taylor G, 2010). The key role of PK2 in neuropathic 
pain is well establish in several animal models, such as chronic constriction injury 
(CCI) of the sciatic nerve, spared nerve injury (SNI) of the same nerve and diabetic 
neuropathy induced by Moderate Low Doses of Streptozotocin (MLD-STZ). 
In the CCI, neuropathic pain is induced by three loose ligatures and it is a model 
associated with infiltrating cells. As reported by studies from my laboratory, sciatic 
nerve ligature is followed by infiltrating cells and PK2 increase is responsible of 
thermal hyperalgesia and contributed to develop of tactile allodynia. Administration 
of PKRs antagonist (PC1 or PC7) prevent the injury-induced overexpression of PK2, 
microgliosis and astrocytes activation in the spinal cord and restored the physiological 
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levels of proinflammatory and anti-inflammatory cytokines (Maftei D. et al., 2014; 
Lattanzi R. et al., 2015). 
Comparable results are showed in SNI model: neuropathy is obtained by transection 
of two of the three terminal branches of the sciatic nerve. Mice develop both thermal 
hyperalgesia and mechanical allodynia that are reverted by PC1 treatment. Moreover, 
PC1 is able to inhibit the PK2-driven glial and microglial activation (Guida F. et al., 
2014).  
In MLD-STZ animal model, diabetic neuropathy is induced by intraperitoneal (i.p.) 
administration of streptozotocin for three consecutive days. Animals develop 
mechanical allodynia and PK2 seems to be implicated both in the early stage of 
allodynia development as well as in its maintenance. The use of PC1 is effective in 
relieving diabetes-induced hypersensitivity, eliminating the PK2 overexpression and 
the peripheral inflammatory status (Castelli M. et al., 2016).  
 
 
2.5. Prokineticins in inflammation and neuroinflammation 
PK system conducts a key role, not only in nociception and pain transmission, but also 
in inflammation/neuroinflammation response. Indeed, elevated levels of PK2 
expression have been detected in infiltrating neutrophils at sites of inflammation 
(LeCouter et al., 2004).  
In a previous study from our group, in the CFA-induced paw inflammation, in situ 
hybridization assays (performed on inflamed paw sections) and qPCR experiments 
(performed on FACS sorted cells) showed that neutrophils (PMN) are the major source 
of PK2 and, more notably, the CFA-induced inflammatory response amplifies PK2 
gene transcription in PMN cells, not only locally in the paw but also systemically 
(Giannini E. et al., 2009). The mechanism of inflammation-induced increase of PK2 in 
granulocytes may depend by the early and rapid increase in plasma levels of 
Granulocyte Colony-Stimulating Factor (G-CSF) in CFA inflamed animals (Bobrowski 
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W. F. et al., 2005). Ferrara’s group demonstrated that G-CSF is the only cytokine able 
to activate PK2 transcription in CD11b+Gr1+ bone marrow-derived cells (Shojaei F. et 
al., 2007). G-CSF is one of principal regulator of granulopoiesis and neutrophil 
mobilization from the bone marrow; thus, the early increase of G-CSF levels in plasma 
of CFA-inflamed animals could explain the systemically enhanced PK2 transcription 
in spleen and paw granulocytes. PK2, released in inflamed tissues, triggers further 
recruitment of macrophages and is able to induce a pro-inflammatory macrophage 
phenotype, increasing cytokines, such as IL-1β and IL-12, and reducing the IL-10 
production (Martucci C. et al., 2006).  
As well as innate response, PK system is involved in adaptive immunity: in fact, PK2, 
trough PKR1, is able to modulate T cell function by reducing T helper (Th)-2 cytokine 
levels, such as IL-4 and IL-10 production, thus indirectly switching the cells towards a 
Th1 and proinflammatory state (Franchi S. et al., 2008).  
As reported in several studies, Prokineticin system dysregulation is involved in in vivo 
and in vitro models of inflammatory and neuroinflammatory state, such as: 
Rheumatoid Arthritis (mouse model of collagen-induced arthritis, CIA), Multiple 
Sclerosis (MS, mouse model of Experimental Autoimmune Encephalomyelitis, EAE), 
inflammatory colitis and in in vitro model of Aβ-induced neurotoxicity. 
In CIA mice, PK2 expression is significantly increased and correlates with the severity 
of arthritis; moreover, immunohistochemical staining of PKRs show that PKR1-
positive cells are predominantly neutrophils infiltrating in the synovial membrane and 
PKR2-positive cells are found in the synovium but associated with macrophage-like 
mononuclear cells (Kurosaka D. et al., 2009; Ito H. et al 2016). 
According to Abou-Hamdan and colleagues, PK2 is an important mediator of MS. 
Indeed, both in mice sera and spinal cord and also in patients sera with MS, PK2 
mRNA is increased, compared to healthy control. In EAE mice, the use of PC7 prevents 
or reduces inflammation and demyelination, decreasing the production of interferon-
γ and interleukin (IL)-17 (Abou-Hamdan M. et al., 2015). 
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Since their discovery, Prokineticins have been shown to modulate contraction of 
smooth muscle derived from various regions of the gastrointestinal (GI) tract and, a 
few years later, it was proven that PK1 is able to stimulate upper GI transit (Wade P. R. 
et al 2009). Successively, in 2011, Watson and colleges have demonstrated that PK2 is 
strongly increased in the GI tract during inflammation, both in biopsy samples 
collected from patients with ulcerative colitis and in tissues samples taken from 
various preclinical models of colitis; this PK2 up-regulation is a direct consequence of 
inflammation: indeed, PK2 mRNA levels positively correlated with IL-1β expression. 
Moreover, authors assume that PK2 modulates the visceral nociception, acting on 
PKRs express by sensory neurons in the gut (Watson R. P. et al., 2012).  
Furthermore, in an in vitro model of Aβ-induced neurotoxicity, it has recently been 
demonstrated that PK2 plays a role in Aβ-mediated neuronal death in cortical primary 
cultures: indeed, following Aβ stimulation, PK2 and its receptors are significantly 
increased at both mRNA and protein level, suggesting that modulation of prokineticin 
system could be a general response to Aβ injury. In addition, the functional 
involvement of the PK system following Aβ stimulation is further demonstrated by 
the ability of Bv8 to induce apoptosis comparable to that induced by Aβ: the Bv8 
neurotoxic activity in cortical brain cultures is achieved with picomolar 
concentrations, indicating that such a low concentration could be compatible with the 
small amount of PK2 eventually released by Aβ stimulation. The use of PC1 
significantly prevents neuronal toxicity by inhibiting the Aβ-induced PK2 increase 
(Severini C. et al, 2015). A recent study indicates also that Aβ insult up-modulates the 
kainate-induced currents in primary cortical cultures and this effect is blocked by PC1 
(Caioli S. et al., 2017).  
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3. AIMS OF THE STUDY 
 
 
 
The immune system constitutes the first line defence against infection or injury and it 
relies on a large family of Pattern Recognition Receptors (PRRs), which trigger 
intracellular signalling cascades ultimately culminating in the expression of a variety 
of proinflammatory molecules, such as cytokines, chemokines, neuropeptides and 
metabolite of the arachidonic acid cascade (Mogensen T. H. et al., 2009). Cytokine and 
chemokines are involved in peripheral inflammation and neuroinflammation, 
conditions that differ for the kind of cells and areas involved. Among the mediators 
responsible of these inflammatory and neuroinflammatory responses, we can now 
include the Prokineticin system. 
Even though these inflammatory states are considered a beneficial response, if 
dysregulated, they can become harmful conditions. Several studies have showed the 
correlation between inflammatory states and many pathologies, including cancer, 
metabolic syndrome, psoriasis, asthma, migraine, Inflammatory Bowel Disease (IBDs), 
major depressive disorder or Alzheimer's disease (AD). 
Given that both PK2 and its receptors are highly expressed in inflammatory and 
neuroinflammatory states, during my Ph.D. I worked on three projects aimed at: 
I. to investigate if the PK system is involved in the protection mechanisms of 
CORT-nursed rats from TNBS-induced experimental colitis 
 
IBDs is the acronym to indicate a group of pathologies that affect colon and 
small intestine and they are characterized by chronic relapsing intestinal 
inflammation. Crohn’s disease and ulcerative colitis are the two-major form of 
IBDs and, although the aetiology of IBDs remains largely unknown, the onset 
involves a complex interaction between the genetic, environmental, microbial 
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factors and the immune responses. In addition to the involvement of cytokines, 
several studies have also indicated that chemokines expression is consistently 
increased during the acute phase of the diseases (Mazzucchelli et al., 1994; 
Puleston et al., 2005).  
To better understood the onset mechanisms of IBDs, many animal models have 
been developed and one of them is the intracolonic infusion of TNBS (2,4,6-
trinitrobenzene sulfonic acid).  
TNBS induces a strong inflammation through its interaction with colon tissue 
proteins, rendering these proteins immunogenic to the host immune system 
(Morris G.P. et al., 1989).  
In a recent study, Petrella and co-workers have demonstrated that adult male 
rats exposed to low doses of corticosterone during lactation (CORT-nursed rats) 
had a reduced vulnerability to TNBS-induced experimental colitis and this 
protection was probably due to the corticosterone-induced alterations in 
intestinal permeability (Petrella C. et al., 2014).  
Watson and colleagues showed that PK2 mRNA was increased in human 
biopsy samples from colitic patients and similar changes were found in rats 
with TNBS-induced experimental colitis, asserting that PK2 is a key mediator 
of the inflammatory response. The authors also presumed that the elevated 
levels of PK2 induced visceral pain via PKR1 activation, the major receptor 
expressed in the gut. Moreover, they claimed that this effect was due not only 
to PK2 but also to PK2β, a peptide derived from proteolytic cleavage of PK2L, 
the splice variant of PK2 (Watson et al., 2012, Giannini et al., 2009). 
Based on these premises, the first aim of my Ph.D. was to better investigate the 
role of PK system in the mechanisms involved in the protection of CORT-
nursed rats from TNBS-induced experimental colitis.  
To address this issue, the mRNA and protein expressions of PK2, PK2L and 
PKRs were evaluated by quantitative Polymerase Chain Reaction (qPCR) and 
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Western Blot (WB) assays in colonic tissues collected from control and CORT-
nursed rats (both healthy and colitic animals) after 4 days from TNBS 
intracolonic instillation. 
II. to characterize the small ligand PK2β, the splice variant of PK2 
 
Despite the numerous studies about Prokineticins, the biological role of PK2L 
and its correlate small peptide PK2β are not well established.  
Chen and co-workers demonstrated that the secreted PK2L protein is processed 
into PK2β peptide by proteolytic cleavage which, in vitro, is a selective ligand 
for PKR1 (Chen J. et al., 2005). 
A previous study from my laboratory demonstrated that in rats and mice 
bearing CFA-induced chronic inflammation in the hind paw, PK2 and PK2L 
expression strongly increased and they are PKR1-mediated.  
Moreover, PK2 and PK2L increase in rat paw correlates with the development 
and duration of inflammatory pain. The pain response has higher intensity and 
longer duration in rats than in mice and this effect was probably due to the 
higher expression of PK2L protein which give rise to PK2β (Giannini E. et al., 
2009). 
Based on these data, the second aim of my Ph.D. was to evaluate the in vivo 
effects of PK2β peptide. For this purpose, I used two nociceptive tests in Wild 
Type (WT) and mice lacking the pkr1 or pkr2 gene:  
▪ Hot Plate test, to measure thermal hyperalgesia (mediated by the afferent 
nociceptive C-fibres, which express mainly PKR1) and  
▪ Von Frey filaments, to measure tactile allodynia (mediated by the activation 
of large diameter myelinated Aβ fibres, which express mainly PKR2)  
Furthermore, I investigated the signalling pathway activated by PK2β in 
organotypic cultures of Dorsal Root Ganglion obtained from WT mice. 
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III. to investigate the role of the Prokineticin system in a non-transgenic animal 
model of Alzheimer's disease 
 
Alzheimer’s disease (AD) is a severe neurodegenerative disorder characterized 
by irreversible memory decline and impaired cognitive functions, correlated 
with the degree of neuronal loss in the brain (Niikura T. et al., 2006). Although 
the aetiology is not yet known, several studies have demonstrated that 
neuroinflammation plays a significant role in the pathogenesis of AD and one 
of the probable cause is represented by the deposition of extracellular 
aggregated amyloid-β (Aβ) in plaques. 
During neuroinflammation numerous mediators are released, such as 
chemokines, that modulate glia activation and, in turn, the neuronal loss. 
Currently, there is no cure for AD and drugs used in therapy can only slow 
down the progression of cognitive and behavioural impairment (McNaull B.B. 
et al., 2010); therefore, most of the researchers have focused their attention to 
understand the onset mechanisms of AD to develop specific drugs. 
Recently, it has been demonstrated that Aβ1-42 treatment induces up-regulation 
of PK2 and its receptors in primary cortical cultures (CNs) and the PKRs 
antagonist, PC1, prevents the neuronal loss by reducing the Aβ-induced PK2 
up-regulation (Severini C. et al., 2015). In addition to the PK2 increase, Aβ1-42-
induced alteration in glutamatergic transmission increasing the AMPA currents 
in CNs and a similar effect is observed with Bv8 (the amphibian homologue of 
PK2) stimulation. This up-modulation of AMPA currents is blocked by PC1 
treatment (Caioli et al., 2017). 
To investigate the involvement of Prokineticin system and the potential effects 
induced by PC1 treatment in vivo, Aβ1-42 peptide was intracerebroventricular 
(i.c.v.) infused in rats and brain samples were collected at given time points. 
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PK2/PKRs mRNA and protein levels were evaluated by qPCR, 
immunofluorescence (IF) and WB assays. 
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4. RESULTS AND DISCUSSION 
 
 
 
I) Investigation of the role of PK system in the mechanisms involved in the 
protection of CORT-nursed rats from TNBS-induced experimental colitis 
 
I.1. Effects of TNBS-induced colitis on colonic PK2/PKRs mRNA and protein 
expression 
Rats were sacrificed at day 4 after TNBS instillation and PK2, PKR1 and PKR2 mRNA 
and protein levels were evaluated by qPCR and Western Blot (WB) assay.  
In colitic control rats, PK2 mRNA levels were significantly increased compared to 
healthy rats, whereas no significative differences (but only a small tendency to 
increase) were observed in CORT-nursed colitic animals compared with CORT-nursed 
healthy rats (Figure 11).  
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Figure 11. Effects of TNBS-induced colitis on colonic PK2 mRNA. The colonic relative mRNA levels 
are expressed in relation to β-actin and presented as fold increase relative to control rats. Data are 
express as mean ± SEM, two-way ANOVA followed by Fisher's LSD post-hoc, ***p<0.001, °°°p<0.001.  
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These data were confirmed by western blot analysis. Interestingly, the increase of PK2 
protein levels was lower in CORT-nursed colitic rats than in control colitic rats (Figure 
12). No differences were found between control and CORT-nursed healthy animals.  
 
 
Figure 12. Effects of TNBS-induced colitis on colonic PK2 protein expression.  
(A) Representative WB analysis showing PK2 protein amount in colonic tissues. (B) Optical density 
(OD) of corresponding WB bands expressed as the ratio of PK2 and β-actin signal. Data are express as 
mean ± SEM, two-way ANOVA followed by Fisher's LSD post-hoc, **p<0.01, °p<0.05 
 
 
In agreement with the PK2 mRNA results, PK2L mRNA levels were increased in 
control colitic rats compared to control healthy animals while no difference was found 
in CORT-nursed colitic animals compared to CORT-nursed healthy rats (Figure 13).  
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It is noteworthy that significant reduction in PK2L mRNA was also observed in CORT-
nursed colitic rats respected to control colitic rats and no differences were observed 
between controls and CORT-nursed healthy animals. The latter result has not been 
confirmed by WB assay, because a specific antibody for PK2L (or for PK2β, the peptide 
product of proteolytic cleavage of PK2L) it was not available. 
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Figure 13. Effects of TNBS-induced colitis on colonic PK2L mRNA expression. The colonic relative 
mRNA levels are expressed in relation to β-actin and presented as fold increase relative to control rats. 
Data are express as mean ± SEM, two-way ANOVA followed by Fisher's LSD post-hoc, ***p<0.001, 
°°°p<0.001.  
 
 
PKR1 mRNA levels and protein expression were not affected by colitis and CORT 
treatment: indeed, as showed in the Figure 14, there were no differences for PKR1 
mRNA and protein between experimental groups. 
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Figure 14. Effects of TNBS-induced colitis on colonic PKR1 mRNA and protein expression. (A) The 
colonic relative mRNA levels are expressed in relation to β-actin and presented as fold increase relative 
to control rats. Data are express as mean ± SEM. (B) Representative WB analysis showing PKR1 protein 
amount in colonic tissues. (C) Optical density (OD) of corresponding WB bands expressed as the ratio 
of PKR1 and β-actin signal. Data are express as mean ± SEM. 
44 
 
Regarding PKR2, its mRNA was significantly increased in colitic rats compared to 
healthy animals and no significant effect of CORT treatment was observed (Figure 15).  
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Figure 15. Effects of TNBS-induced colitis on colonic PKR2 mRNA expression. The colonic relative 
mRNA levels are expressed in relation to β-actin and presented as fold increase relative to control rats. 
Data are express as mean ± SEM, two-way ANOVA followed by Fisher's LSD post-hoc, ***p<0.001.  
 
Conversely, there were no differences in PKR2 protein expression between groups 
(Figure 16). 
 
 
Figure 16. Effects of TNBS-induced colitis on colonic PKR2 protein expression. (A) Representative 
WB analysis showing PKR2 protein amount in colonic tissues. (B) Optical density (OD) of 
corresponding WB bands expressed as the ratio of PKR2 and β-actin signal. Data are express as mean ± 
SEM. 
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I.2. Effects of TNBS-induced colitis on the pro-inflammatory cytokines IL-1β and 
TNF-α 
qPCR analysis showed that inflammatory colitis induced a significant increase in the 
mRNA levels of IL-1β (Figure 17 A) and TNF-α (Figure 17 B) in control colitis rats, 
compared to control healthy animals, while no modification of these pro-inflammatory 
cytokines was observed in CORT-nursed colitic rats, in comparison with CORT-
nursed healthy rats. Moreover, CORT-nursed colitic rats had lower levels of IL-1β and 
TNF-α mRNA, with respect to control colitic animals. No differences were observed 
between control and CORT-nursed healthy animals. 
 
 
 
Figure 17. Effects of TNBS-induced colitis on colonic IL-1β and TNF-α mRNA expression.  
The colonic relative mRNA levels of IL-1β (A) and TNF-α (B) are expressed in relation to β-actin and 
presented as fold increase relative to control rats. Data are express as mean ± SEM, two-way ANOVA 
followed by Fisher's LSD post-hoc, ***p<0.001; °°°p>0.001.  
 
 
 
I.3. Discussion 
The results here presented are a section of a project conducted in collaboration with 
Dr. Casolini’s group and my assignment was to investigate the involvement of PK 
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system in the protection mechanisms of CORT-nursed rats from TNBS-induced 
experimental colitis (for any further details, please refer to Zinni et al., 2017). 
The term “CORT-nursed” is used to indicate offspring nursed from mothers with mild 
hypercorticosteronaemia developed by drinking water supplemented with 
corticosterone (0.2 mg/ml). The corticosterone assumed through breast milk is easily 
absorbed by the gastrointestinal tract of the pups. Once adults, these rats showed 
improved learning capabilities, reduced fearfulness in anxiogenic situations, 
persistent hypo-reactivity of the hypothalamus-pituitary-adrenal axis due to an 
increased number of glucocorticoid receptors (GR) in the hippocampus and resistance 
to ischemic neuronal damage (Casolini P. et al., 2007; Catalani A. et al., 2011).  
A recent study demonstrated that adult CORT-nursed rats are protected against 2,4,6-
trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis: indeed, they 
showed an improvement in some indices of pathology (such as loss of body weight 
and food intake, increased colonic myeloperoxidase activity and mast-cell 
degranulation) with respect to colitic control animals (adult male offspring whose 
mothers drank tap water during lactation). Here, we have investigated the cellular 
actors involved in the protection mechanisms of CORT-nursed rats in TNBS-induced 
experimental colitis.  
Glucocorticoids (GCs) are able to activate the cytosolic GR, assembling a ligand-
receptor complex that translocates into the nucleus where interacts with the promoter 
regions of different genes such as Glucocorticoid-Induced Leucine Zipper (GILZ). 
GILZ has immuno-modulatory activity that involves a physical interaction between 
GILZ itself and the transcription factors that regulate the expression of pro-
inflammatory genes (Ronchetti S. et al., 2015) such as the transcription Nuclear Factor 
κB (NF-κB). Data from literature show that NF-κB promotes the transcription of pro-
inflammatory genes such as IL-1β and TNF-α (Tak P. P. et al., 2001) and this effect is 
inhibited by the physical interaction of GILZ with the p65 subunit of NF-κB (Ayroldi 
E. et al., 2001; Riccardi C. et al., 2001). In the study conducted by Zinni, it has been 
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demonstrated that GILZ is significantly increased in CORT-nursed colitic rats and its 
over-expression reduced the colonic NF-κB activation (data not show, remind to Zinni 
et al., 2017) and, in turn, the expression of the pro-inflammatory cytokines IL-1β and 
TNF-α, as show here by qPCR analysis.  
During inflammatory processes, cytokines are released together with other molecules 
such as chemokines belonging to the Prokineticins family (Negri L. and Lattanzi R., 
2011). Indeed, it is already demonstrated that in inflammatory conditions, PK2 and its 
splice variant PK2L are strongly augmented (Giannini E. et al., 2009) and that the 
increase of IL-1β is correlated with the up-regulation of PK2 (Franchi S. et al., 2008). 
This PK2 increase is also confirmed by Watson in TNBS-induced colitis (Watson R. P. 
et al., 2012).  
In this study, PK2 (both mRNA and protein) and PK2L mRNA expressions are 
increased in colitic rats and these increases are of minor entity in colitic CORT-nursed 
rats compared to control colitic rats. This protection could be ascribed to the 
relationship between NF-κB and the Prokineticin system. Indeed, it has been 
demonstrated that NF-κB is able to regulate the expression of the Bo8 gene (a Bv8 
homologue from Bombina orientalis) and that the consensus sequence for NF-κB 
identified in the Bo8 promoter is similar to those present in the promoter regions of 
mammalian homologs PK2 (Marsango S. et al.,2009). 
Concerning the prokineticin receptors, PKR1 is the major receptor express in the GI 
tract and data from qPCR and WB assays show no differences in PKR1 expression after 
TNBS intracolonic instillation, while PKR2 mRNA expression is increased after TNBS-
induced colitis; this is in accordance with previous evidence that suggested PKR2 as 
the inducible receptor (Maftei D. et al., 2014; Kisliouk T. et al., 2005). Conversely, PKR2 
protein expression levels are unchanged. There are two possibilities that can explain 
this discrepancy: the first is that PKR2 mRNA and protein expression are performed 
at only one-time point (four days after TNBS instillation), without performing a time-
course and it cannot exclude that PKR2 mRNA up-regulation has just started at day 4 
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after TNBS intracolonic instillation whereas the protein expression can occur later. The 
second theory regards the transcription mechanisms of mRNA in protein: indeed, 
there is no direct relationship between the concentration of a transcript and the 
concentration of its protein, as reported by Liu and colleagues (Liu Y. at al., 2016).  
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II) Characterization of the small ligand PK2β 
 
 
 
II.1. Evaluation of thermal hyperalgesia and tactile allodynia 
The effect of PK2β on nociceptive thresholds to thermal and tactile stimuli was 
evaluated using two behavioural tests: Hot Plate test and Von Frey filaments in wild-
type (WT) mice and PKR1- or PKR2-null mice (Figure 18).  
In WT mice, PK2β intraplantar (i.pl.) injection induced a dose-dependently thermal 
hyperalgesia (Hot Plate test, Figure 18 A) which peaked 30 minutes after i.pl. 
administration and lasted about two hours: the dose of 10 fmol induced a slight non-
significant thermal hyperalgesia, whereas at 30 fmol nociceptive threshold to thermal 
stimuli was decreased by 28%.  
The higher dose of 60 fmol diminished the nociceptive threshold by 43%. These effects 
were comparable to those induced by PK2 i.pl. administration (Figure 18 B). Indeed, 
PK2 30 and 60 fmol decreased the nociceptive threshold to thermal stimuli by 24% and 
40%, respectively. The same doses of PK2 also induced tactile allodynia (evaluated by 
Von Frey filaments, Figure 18 D), which peaked 60-90 min after administration and 
lasted about three hours.  
Conversely, PK2β 30 and 60 fmol were almost ineffective in inducing sensitization to 
tactile stimuli (Figure 18 C). Indeed, the higher dose of 60 fmol was able to significantly 
decrease the nociceptive threshold to tactile stimuli by only 25%, whereas the same 
dose of PK2 induced a strong and long-lasting tactile allodynia.  
Mice lacking PKR1 or PKR2 are less sensitive than wild-type mice to PK2β (Figure 18 
E).  
Administration of PK2β 600 fmol (a dose ten times larger) induced a significant 
decrease (36%) of thermal nociceptive threshold in PKR2-KO mice. In PKR1-null mice, 
600 fmol of PK2β was almost ineffective in inducing thermal hyperalgesia. 
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Figure 18. Time-course of percentage decrease in nociceptive threshold (% ΔNT) elicited in mice after 
i.pl. injection of PK2β and PK2.Effect of intraplantar injection of 10, 30 and 60 fmol of PK2β (A, C) and 
PK2 (B, D) on the nociceptive threshold to thermal (Hot Plate test) and tactile stimuli (Von Frey 
filaments). Effect of intraplantar injection of PK2β 600 fmol in PKR1- and PKR2-KO mice compared to 
WT mice (E). The data represent means ± SEM of six mice. Two-way ANOVA was used for statistical 
evaluation, followed by the Bonferroni’s test. *** p<0.001, **p<0.01, * p<0.05 compared with CTRL group. 
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II.2. Evaluation of PK2β-induced PKR1 activation in organotypic cultures of DRG 
To assess the ability of PK2β to activate PKR1 coupled to Gαi protein, we evaluated 
the STAT3 phosphorylation by WB assay in mice DRG organotypic cultures (Figure 
19). The cultures were stimulated for 1 hour with PK2, PTX (Gαi protein inhibitor) 
(Burns D. et al., 1988) plus PK2 or PK2β. As shown in the Figure, PK2 induces tyrosine 
phosphorylation of STAT3, according to literature, whereas PK2β does not induce 
phosphorylation. 
 
Figure 19. PK2β does not induce STAT3 activation. Western blot analysis showing representative 
bands of phospho-STAT3 (p-STAT3) and STAT3 protein. Values are means ± SEM of three replications 
for each antibody, performed on three separate pools. One-way ANOVA was used for statistical 
evaluation, followed by Tukey’s test for multiple comparisons. *** p<0.001 PK2 vs CTRL. 
 
 
II.3. Discussion 
Alternative splicing is a fine-regulated process during gene expression which allows 
to a single gene to encode for multiple proteins increasing the cellular biodiversity. It 
occurs as a normal phenomenon in eukaryotes and several mechanisms have been 
observed.  
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Prokineticins are proteins capable of generating a wide variety of responses, thanks to 
specific tissue distribution and/or cellular targets in different organisms and cell types 
(LeCouter J. et al., 2003b). Two isoforms arising from a PK2 gene through alternative 
splicing have been identified in humans and mice, and named PK2 and PK2L 
(Wechselberger C. et al., 1999; Chen J. et al, 2005): PK2 is formed by 3 exons (exons 1, 2 
and 4) whereas PK2L is formed by 4 exons (1, 2, 3 and 4 exons) which contain 21 
additional basic residues. PK2 mRNA is found in all tissues, whereas PK2L mRNA 
expression is found to be highest in the lung and spleen, barely detected in the brain, 
and undetectable in the kidney (Negri L. et al., 2007). 
It is known that the ligand PK2 has diverse physiological effects depending on tissues 
expression (Guilini C. et al., 2010), but the physiological role of PK2L/PK2β is not well 
established. The information so far available indicate that PK2L has a very poor 
biological activity and, when it is cleaved by extracellular proteases in the smaller 
peptide PK2β, results a selective ligand for PKR1 in vitro (Chen J. et al., 2005).  
In this study, the activity of PK2β is better investigated. Previous data have shown that 
intraplantar injection of Bv8/PK2 produces an intense nociceptive sensitization to both 
thermal and tactile stimuli (Negri L. et al., 2002).  
Here, we demonstrate that local injection of PK2β behaves like Bv8/PK2, being capable 
of strong decrease the nociceptive threshold of mice only when they are subjected to 
thermal but not tactile stimuli. Considerable evidences indicate that thermal 
hyperalgesia and tactile allodynia are mediated through different neuronal pathways 
(Yeomans D. C. and Proudfit H. K, 1996; Ossipov M. H. et al., 1999). Thermal hyperalgesia 
is most likely mediated by the afferent nociceptive C-fibres, which express mainly 
PKR1, whereas tactile allodynia seems to be mediated by the activation of large 
diameter, myelinated Aβ fibres, which express mainly PKR2 (Ossipov M. H. et al., 1999; 
Negri L. et al., 2006; Vellani V. et al., 2006). Moreover, in a previous study is 
demonstrated that tactile allodynia is equally evoked by Bv8 in WT and PKR1-null 
mice, suggesting that PKR2 receptor is involved in nociceptor sensitization to punctate 
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stimuli (Negri L. et al., 2006). All these data allow us to argue that PK2β is able to bind 
and activate PKR1 in vivo. Indeed, these results are further confirmed by pain 
behavioural experiments on PKRs-KO mice. Indeed, we demonstrate that the dose of 
PK2β that can induce strong thermal hyperalgesia in PKR2-KO mice is ineffective in 
PKR1-KO mice. 
In this work we demonstrated (data not shown) that in different yeast strains 
expressing selectively PKR1 coupled to Gαs, Gαq or Gαi subunit, PK2 was able to 
activate all of them subunits whereas, PK2β was capable to activate PKR1 coupled 
with Gαs or Gαq but not Gαi. To confirm this data, we analysed STAT3 
phosphorylation in mice DRG organotypic cultures. STAT3 is a transcriptional factor 
activate in response to cytokines and grow factors and its phosphorylation is due to 
activation of subunit Gαi protein. As demonstrated by WB assay, PK2β is not able to 
induce STAT3 activation in mice organotypic cultures of DRG.  
These results contribute to the understanding of the PK ligands and receptors function 
and which different responses will be generated in different cell types, depending on 
which ligand-receptor-G protein combination is expressed. 
  
54 
 
III) Investigation of the role of Prokineticin system in a non-transgenic 
animal model of Alzheimer's disease 
 
 
 
III.1. Biochemical assays in prefrontal cortex (PFC) and hippocampus 
To investigate the role of the Prokineticin system in an in vivo animal model of 
Alzheimer's disease, time course analysis of PK2 and PKRs mRNA levels in prefrontal 
cortex (PFC) and hippocampus were performed by qPCR. Tissues were collected at 1, 
7, 14 and 35 days after Aβ1-42 or vehicle i.c.v. infusion (Figure 20). 
At day 35 after i.c.v. infusion, PK2 and PKRs protein expressions were evaluated by 
immunofluorescence (IF) assay in PFC and by IF and Western Blot (WB) in 
hippocampus. 
 
 
Figure 20. Experimental timeline. Rats received infusion of Aβ1-42 or Vehicle into the left lateral 
ventricle. PC1 treatment (150 µg/kg s.c. 2 times a day for 14 days) started on the day of surgery and 
ended at day 14. Tissues were collected at time-points indicated in the image.  
 
 
III.2. Evaluation of PK2/PKRs in prefrontal cortex (PFC) 
In Vehicle infused rats, basal levels of PK2, PKR1 or PKR2 mRNA were negligible. 
Aβ1-42 i.c.v. infusion modulated PK2 and PKRs mRNA expression levels. Indeed, PK2 
and PKR2 mRNA levels were significantly increased already at day 1 (Figure 21) and 
remained at the same level up to 35 days. PKR1 mRNA showed a constant tendency 
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to increase up to 14 days, reaching the statistical significance at day 7 after Aβ1-42 
infusion.  
PC1 administration (150 μg/kg, s.c. 2 times a day for 1, 7 or 14 days, starting at the day 
of Aβ1-42 infusion) had no effect on PKRs mRNA overexpression, but it tended to 
reduce PK2 mRNA levels even if the values did not reach the statistical significance. 
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Figure 21. Time-course analysis of PK2, PKR1 and PKR2 mRNA expressions in prefrontal cortex of 
Aβ1-42 or Veh i.c.v. infused rats. Data represent means ± SEM of five rats. Analysis were performed with 
Two-way ANOVA, followed by Bonferroni’s test. **p < 0.01, ***p < 0.001.  
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Immunofluorescence analysis, performed 35 days after Aβ1-42 infusion, showed an 
increase of PK2 immunofluorescence signal (Figure 22 A) in neurons of prefrontal 
cortex, as demonstrated by the colocalization with NeuN (neuronal marker). PKR1 
immunofluorescence signal was slightly increased after Aβ1-42 infusion in PFC neurons, 
as demonstrated by the colocalization with NeuN, compared with Vehicle infused rats 
where the signal was undetectable (Figure 22 B).  
 
 
Figure 22. Expression of PK2, PKR1 and PKR2 in the PFC of Vehicle/Vehicle, Vehicle/PC1, Aβ1-
42/Vehicle and Aβ1-42/PC1 rats. Immunofluorescence double-staining of PK2 (A), PKR1 (B) and PKR2 
(C) - green with NeuN (neuronal marker) – red. Cell nuclei were counterstained with DAPI (blue 
fluorescence). Scale bar, 30 µm. 
 
In the same area, PKR2 immunofluorescence signal (Figure 22 C) was present in 
neurons of Vehicle infused rats, as demonstrated by the colocalization with NeuN. 
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Aβ1-42 infused rats, PKR2 immunofluorescence signal only slightly increased in PFC 
neurons.  
PC1 treatment displayed a tendency to decrease the PK2 immunofluorescence signal 
but had no effect on PKRs.  
 
 
 
III.3. Evaluation of PK2/PKRs expression in hippocampus 
In hippocampus, time-course analysis of mRNA expression showed a strong 
activation of PK system (Figure 23).  
In Aβ1-42 injected rats, PK2 mRNA levels were increased already at day 1 after i.c.v. 
infusion and reached the maximum after 14 and 35 days,  
PKR1 mRNA showed ups and downs expression pattern with a not significant 
increase at day 1, a decrease at day 7 followed by a significant increase at day 14 and 
then a decrease at day 35.  
PKR2 mRNA expression showed the similar ups and downs expression pattern of 
PKR1 with a significant increase at days 1 and 14 and a decrease at days 7 and 35 after 
Aβ1-42 infusion. 
PC1 administration (150 μg/kg, s.c. 2 times a day for 1, 7 or 14 days) significantly 
decrease PK2 mRNA levels starting from day 7 after Aβ1-42 i.c.v. infusion and had no 
effects on PKR2 mRNA expression levels. 
Interestingly, PC1 treatment increased PKR1 mRNA levels, compared to Aβ1-42 injected 
rats even if the values did not rich a statistical significance.  
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Figure 23. Time-course analysis of mRNA PK2, PKR1 and PKR2 expression in hippocampus of Aβ 
or vehicle i.c.v. infused rats. Data represent means ± SEM of five rats. Analysis were performed with 
Two-way ANOVA, followed by Bonferroni’s test. *p < 0.05; **p < 0.01, ***p < 0.001.  
 
Proteins analysis of PK2 and PKRs were performed on samples collected at day 35 
after Aβ1-42 or vehicle i.c.v. infusion by western blot (WB) and IF assays.  
In hippocampus of Aβ1-42 injected rats, WB analysis showed a significant increase of 
PK2 (Figure 24) and PKR1(Figure 26) protein levels compared to Vehicle injected rats, 
confirming the results obtained by mRNA analysis at day 35.  
Regarding PKR2 (Figure 28), no differences in protein levels were found between the 
experimental groups. PC1 treatment significantly reduced PK2 protein levels (Figure 
24) and strongly increased PKR1 protein expression (Figure 26) in hippocampus. 
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Figure 24. PK2 protein expression in hippocampus of Vehicle/Vehicle, Aβ1-42/Vehicle, Aβ1-42/PC1 and 
Vehicle/PC1 rats. (A) Representative WB analysis showing PK2 protein amount in hippocampus. (B) 
Optical density (OD) of corresponding WB bands expressed as the ratio of PK2 and β-actin signal. Data 
are express as mean ± SEM. (C) Immunofluorescence staining of PK2 (green) in CA1, CA2, CA3 and 
DG. Cell nuclei were counterstained with DAPI (blue fluorescence). Scale bar, 50 µm. 
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Figure 25. PK2 cellular localization in the hippocampus. Immunofluorescence double-staining of PK2 
– green - and (A) GFAP (astrocytic marker), (B) NeuN (neuronal marker) and (C) CD11b (microglial 
marker) – red. Cell nuclei were counterstained with DAPI (blue fluorescence). Scale bar, 10 µm. 
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Figure 26. PKR1 protein expression in the hippocampus of Vehicle/Vehicle, Aβ1-42/Vehicle, Aβ1-42/PC1 
and Vehicle/PC1 rats. 
(A) Representative WB analysis showing PKR1 protein amount in hippocampus. (B) Optical density 
(OD) of corresponding WB bands expressed as the ratio of PKR1 and β-actin signal. Data are express as 
mean ± SEM.(C) Immunofluorescence double-staining of PKR1 - green with NeuN (neuronal marker) – 
red in CA1, CA2, CA3 and DG. Cell nuclei were counterstained with DAPI (blue fluorescence). Scale 
bar, 50 µm. 
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IF studies were performed on hippocampus and expression levels of PK2 and PKRs in 
CA1, CA2, CA3 and dentate gyrus (DG) were evaluated. In these areas, PK2 
immunofluorescence signal (Figure 24) was strongly increased in CA1, CA2 and CA3 
but not DG of Aβ1-42 injected rats, compare to Vehicle i.c.v. injected animals (where the 
PK2 signal was faint), confirming the results obtained by WB assay.  
PK2 immunoreactivity was localized in neurons and some astrocytes (as demonstrated 
by the colocalization with NeuN and GFAP, neuronal and astrocyte markers, 
respectively, Figure 25) but not in microglia. PC1 treatment was able to decrease the 
PK2 immunofluorescence signal in these areas.  
In Vehicle infused rats, PKR1 immunofluorescence signal was faint in all the 
hippocampal regions investigated (Figure 26) and IF signal was localized mainly in 
the neurons, as demonstrated by colocalization with NeuN (Figure 27).  
Aβ1-42 infusion increased PKR1 signal in neurons and astrocytes mainly in CA1 and 
CA2 areas. Interestingly, as already showed by WB assay, PC1 treatment increased 
PKR1 immunofluorescence signal, mostly in CA2 and CA1 regions.  
In Vehicle infused rats, PKR2 signal was localized in neurons of CA1, CA2 and CA3 
but not DG (Figure 29), as demonstrated by the colocalization with NeuN, but not in 
astrocytes or microglia.  
Aβ1-42 i.c.v. infusion slowly increase the PKR2 immunofluorescence signal in neurons 
and PC1 treatment did not change the PKR2 immunofluorescence signal in 
hippocampus, according to WB assay. 
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Figure 27. PKR1 cellular localization in the hippocampus. Immunofluorescence double-staining of 
PKR1 – green - and (A) GFAP (astrocytic marker), (B) NeuN (neuronal marker) and (C) CD11b 
(microglial marker) – red. Cell nuclei were counterstained with DAPI (blue fluorescence). Scale bar, 10 
µm. 
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Figure 28. PKR2 protein expression in hippocampus of Vehicle/Vehicle, Aβ1-42/Vehicle, Aβ1-42/PC1 
and Vehicle/PC1 rats.  
(A) Representative WB analysis showing PKR2 protein amount in hippocampus. (B) Optical density 
(OD) of corresponding WB bands expressed as the ratio of PKR1 and β-actin signal. Data are express as 
mean ± SEM. (C) Immunofluorescence double-staining of PKR2 - red - with GFAP (astrocytic marker) – 
green - in CA1, CA2, CA3 and DG. Cell nuclei were counterstained with DAPI (blue fluorescence). Scale 
bar, 50 µm. 
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Figure 29. PKR2 cellular localization in the hippocampus. Immunofluorescence double-staining of 
PKR2 – green - and (A) GFAP (astrocytic marker), (B) NeuN (neuronal marker) and (C) CD11b 
(microglial marker) – red. Cell nuclei were counterstained with DAPI (blue fluorescence). Scale bar, 10 
µm. 
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III.4. Aβ1-42 i.c.v. infusion induces neuroinflammation, glia activation and neuronal 
death 
In hippocampus of Aβ1-42 injected rats, iNOS and phospho-NF-κB p65 (Ser536) protein 
levels (a marker of activation of NF-κB, a transcriptional factor activated by 
inflammatory stimuli) were statistically increased compared to Vehicle injected rats 
(Figure 30). 
PC1 treatment was able to restore the physiological levels of these proteins. 
 
 
 
Figure 30. Neuroinflammatory markers in hippocampus. Representative WB analysis showing iNOS 
(A) and phospho-p65 (B) proteins amount in hippocampus. In graphs are showed the Optical Density 
(OD) of corresponding WB bands expressed as the ratio of iNOS or phospho-p65 and β-actin signal. 
Data are express as mean ± SEM. 
 
 
GFAP (astrocytic marker) and Iba-1 (microglial marker) protein levels were 
statistically increased in hippocampus of Aβ1-42 injected rats compared to Vehicle 
injected rats (Figure 31); these data were according to IF assay where the 
immunofluorescence signal of GFAP and CD11b (astrocytic and microglia markers, 
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respectively) were increased. PC1 treatment was able to reduce the activation of 
astrocytes and microglia in Aβ1-42 injected rats.  
 
 
 
Figure 31. Activation of microglia and astrocytes in hippocampus. Representative WB analysis 
showing GFAP (A, left) and Iba-1 (B, left) proteins amount in hippocampus. In graphs are shown the 
Optical Density (OD) of corresponding WB bands expressed as the ratio of GFAP or Iba-1 and β-actin 
signal. Data are express as mean ± SEM. Immunofluorescence staining of GFAP (astrocytic marker) – 
green - (A, right) and CD11b (microglial marker) – red (B, right). Cell nuclei were counterstained with 
DAPI (blue fluorescence). Scale bar, 30 µm. 
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Aβ1-42 infusion induced neuronal death in rat hippocampus, as demonstrated by a 
decrease protein levels of MAP2 compared to Vehicle injected rats (Figure 32 A). 
 
 
 
Figure 32. Neuronal markers in hippocampus. Representative WB analysis showing MAP2 (A) and 
Doublecortin (DCX) (B) proteins amount in hippocampus. In graphs are shown the Optical Density 
(OD) of corresponding WB bands expressed as the ratio of MAP2 or DCX and β-actin signal. Data are 
express as mean ± SEM. Immunofluorescence (C) double staining of DCX – green - and NeuN – red 
(neuronal marker). Cell nuclei were counterstained with DAPI (blue fluorescence). Scale bar, 30 µm. 
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PC1 treatment diminished neuronal death, as demonstrated by the increase of WB 
signal. WB analysis showed a significant decrease of DCX (Doublecortin, a 
neurogenesis marker) protein levels in the hippocampus of Aβ1-42 injected rats 
compared to control group (Figure 32 B) and PC1 treatment was able to restore protein 
levels. These data were in accordance to IF assay that showed a decrease of DCX 
immunofluorescence signal in DG compare to Vehicle injected rats. PC1 treatment was 
able to counteract Aβ-induced DCX reduction and restored the hippocampal 
neurogenesis.  
 
 
III.5. Discussion 
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disorder and is 
the principal cause of dementia in the elderly, representing a big issue for human 
health worldwide.  
AD patients manifest cognitive decline and deficits in social competence and the 
causes are not completely understood. Compared to previous years, steps forward 
have been made and neuroinflammation seems to play a key role: indeed, the 
abnormal production of pro-inflammatory cytokines and chemokines in AD brains 
drive to microglia and astrocytes activation that lead to neuronal damage (Lyman M. 
et al.,2014).  
Neuropathological hallmarks of AD correlate with the alteration in the production or 
clearance of β amyloid (Aβ) peptides and neurofibrillary tangles formation. (Cleary J. 
P. et al., 2010). Aβ has been so far one of the most important targets for the development 
of drugs in the AD treatment (Hardy J. and Selkoe, D. J., 2002). Nowadays, drugs used 
in therapy can only slow down the progression of cognitive and behavioural 
impairment (McNaull B.B. et al., 2010). 
In a recent study, Severini and co-workers demonstrated that PK system is modulated 
in response to Aβ injury in vitro. Indeed, in primary cortical cultures (CNs), Aβ1-42 
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peptide increases the mRNA and protein levels of PK2/PKRs and the PKRs antagonist, 
PC1, dose-dependently protects CNs against Aβ1-42-induced neurotoxicity by reducing 
the PK2 up-regulation (Severini C. et al., 2015). 
Here, we have analysed the involvement of the PK system and the possible role of the 
PKRs antagonist PC1 in vivo, in a non-transgenic animal model of Alzheimer's disease, 
induced by intracerebroventricular (i.c.v.) infusion of Aβ1-42 peptide. 
According to previous in vitro data, PK2 mRNA is modulated already at day 1 after 
Aβ1-42 i.c.v. infusion in both prefrontal cortex (PFC) and hippocampus, suggesting that 
PK2 increase is an early response to Aβ injury. Accordingly, PK2 protein level is 
increased in response to Aβ1-42 peptide both in neurons and astrocytes and its 
expression is reduced by PC1 administration. 
The PKRs mRNA and protein expression levels are also increased by Aβ1-42 i.c.v. 
administration but only in the PFC. PKR1 and PKR2 immunoreactivity signals are 
localized in prefrontal neurons. PC1 treatment has no effect on PKRs expression levels.  
In hippocampus of Aβ infused rats, PKR1 shows a tendency to increase and the 
treatment with PC1, the PKRs antagonist, induces an additional increase of its 
expression even if it is not statistically significant. Immunofluorescence (IF) assay 
confirms its increase, mainly in neurons of CA2 and CA1 areas.  
Recently, new neuronal circuits were found in hippocampus, such as DG-CA2-CA1 
circuit: new-born neurons in DG project to pyramidal neurons in CA2 area and then 
to the neurons in CA1, this circuit provides an information transfer in the dorsal and 
ventral directions of the hippocampus and seems to be involved in declarative learning 
(Dudek S.M. et al., 2016).  
We suppose that PKR1 is probably involved in learning processes. The functional 
involvement of PKR1 in learning processes is sustained by the ability of PC1, which is 
a PKR1 preferring antagonist, to increase the DG neurogenesis and to improve the 
cognitive behavioural tasks in Aβ1-42 infused rats (Morris Water Maze test, data not 
show).  
71 
 
As far as concerned PKR2, its mRNA is increased after Aβ infusion, but neither 
Western Blot (WB) or IF assays show any modulation of the protein. PKR2 is usually 
augmented both as mRNA and as protein in other animal models of inflammation or 
neuropathy (Maftei D. et al., 2014; Kisliouk T. et al., 2005) and, probably, this discrepancy 
between PKR2 mRNA levels and protein expression is due to absence of a linear 
correlation between mRNA abundance and protein, because it is a fine-regulated 
process by several cellular mechanisms. (Liu Y. et al., 2016). 
The resident immune cells of the CNS, microglia and astrocytes, are considered the 
primary cell types involved in the innate immune response in the brain. Biochemical 
analysis of hippocampal tissues display activation of astrocytes and microglia, as 
showed by GFAP and Iba-1/CD11b increase. This process occurs both in acute injury 
and in chronic neurodegenerative disorders. Probably, as suggested by numerous 
studies, astrocytes can form a protective barrier between Aβ deposits and neurons but, 
in response to chronic stress (such as pro-inflammatory cytokines), they could 
overexpress BACE1 enzyme, becoming a source of Aβ peptides themselves (Roßner S. 
et al., 2005).  
Furthermore, microglia activation can drive to the synthesis of cytokines, chemokines 
and neurotoxic factors as demonstrated by activation of NF-κB (here showed by 
phospho-p65 protein increase). These molecules amplify neuroinflammation which 
lead to neuronal loss (Walter S. et al., 2007) as proved by the decrease of MAP-2 protein 
levels. 
The functional involvement of the PK system in Aβ-induced toxicity is further 
demonstrated by the ability of PC1 to exert simultaneously anti-inflammatory and 
neuroprotective effects. Indeed, PC1, not only decreases the up-regulation of PK2, but 
is able to reduce the glial activation, as demonstrated by the decrease of GFAP and 
Iba-1/CD11b signals. Moreover, the use of the PKRs antagonist impairs the activation 
of NF-κB, reducing the transcription of its target genes, such as cytokines and 
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chemokines. Our results further show that PC1 restores the physiological levels of 
MAP-2, suggesting the reduction of Aβ-induced neuronal death.  
Data from literature report that, in addition to glial activation and massive release of 
pro-inflammatory molecules, other mechanisms are involved in neuronal damage. 
Among these mechanisms there are impaired hippocampal neurogenesis and 
imbalance between GABAergic and glutamatergic neurotransmission.  
Neurogenesis occurs in dentate gyrus and persists through adulthood in rodents and 
humans. It regulates hippocampal plasticity and is critical for memory and learning 
processes (James B. A. et al., 2014). It is tightly regulated by neuronal activity and, in 
particular, by the balance between GABAergic and glutamatergic inputs (Zhao et al., 
2008). Aβ peptide is able to affect adult neurogenesis by altering the balance between 
excitatory and inhibitory inputs onto neurons (Sun B. et al., 2009). As demonstrated by 
Caioli and colleagues, Bv8 (the amphibian homologue of PK2), as well as the Aβ1-42 
insult, is able to alter glutamatergic transmission, augmenting the AMPA currents in 
neurons and this effect is blocked by PC1 treatment (Caioli S. et al., 2017). According to 
the literature, in this study, we observe impaired neurogenesis in Aβ1-42 infused rats 
and PC1 is able to restore the physiological neurogenesis. Probably, this effect is due 
to its ability to block the up-modulation of glutamatergic neurotransmission, as 
mentioned above.  
Taken together, these results indicate that PK system plays a role in Aβ-induced 
toxicity in vivo, representing an innovative approach for the study of AD 
etiopathology. Moreover, the pharmacological block of PKRs seems to be a good 
strategy for a potential AD treatment.  
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5. CONCLUSIONS 
 
 
 
Nowadays, it is accepted that the Prokineticin system has a great relevance in a variety 
of physiological and pathological states. 
The data that I presented in this work, demonstrate a clear involvement of the PK 
system in inflammatory/neuroinflammatory processes employed in colitis and in 
neurodegenerative pathology of Alzheimer’s disease. 
Blocking the Prokineticin system may be a good potential strategy for the 
pharmacological treatment of these diseases. 
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6. MATERIALS AND METHODS 
 
 
 
6.1. Animals 
All experiments were carried out in: 
Rats: 
- Female Wistar rats (Charles River, Calco, Italy) weighing 280–320 g were mated and 
their offspring were used for experimental procedures. 
-Male Sprague-Dawley rats (Charles River, Calco, Italy) weighing 280-320g at the time 
of surgical procedure. Animals were housed two for cage. 
Mice: 
-Male C57BL/6J wild type (WT), PKR1- or PKR2-null mice, generated by Lexicon 
Genetics (The Woodlands, TX, USA) weighing 25-30 g. Animals were kept in a 
temperature and humidity-controlled room (22 ± 2°C, 50–60%), with access to water 
and food ad libitum.  
Each protocol was approved by the Animal Care and Use Committee of the Italian 
Ministry of Health according to European Commission directives and all efforts were 
made to minimize the number of animals and their suffering. 
 
6.2. Procedures 
6.2.1. CORT-nursed model and colitis induction (TNBS intracolonic infusion) 
This procedure was performed by Dr. Casolini's research group. 
Female Wistar rats, were mated and then housed individually. After the birth, mothers 
and their offspring had ad libitum access to a solution of 0.2 mg/ml hemisuccinate 
corticosterone (CORT-nursed rats) or tap water (control rats) until weaning (day 21 
after birth) and then housed three per cage.  
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Three-month-old male CORT-nursed rats and their controls were used for further 
experiments. At the beginning of the experiment, male rats were housed one per cage 
until their sacrifice. 
Colitis was induced by instillation of TNBS (2,4,6-trinitrobenzenesulphonic acid) 
(Sigma Aldrich, St Louis, MO, USA) at the dose of 30 mg/kg in 0.3 ml of 50% ethanol 
(vol/vol). Animals were anesthetised by intraperitoneal (i.p.) injection of xylazine (0.6 
mg/kg) and ketamine (120 mg/kg) and were randomized into two groups: 1) healthy 
rats (both control and CORT-nursed rats) infused with 0.3 ml of vehicle and 2) colitic 
rats (both control and CORT-nursed rats) infused with TNBS. The infusion was 
performed through a silicone catheter (with an external diameter of 2 mm) introduced 
into the distal colon, 6 cm proximal to the anus and then, rats were held in a head-
down position for 2–3 min, to distribute the agents within the entire colon. (Morris G.P. 
et al., 1989). On the fourth day after TNBS or vehicle instillation, all animals were 
euthanized by CO2 inhalation and, for each experimental group, colonic tissue was 
collected and stored at -80° C until use. In this study, the total number of rats analysed 
was 17 divided as follows: control healthy (n = 4), control colitic (n = 5), CORT-nursed 
healthy (n = 4) and CORT-nursed colitic (n = 4). 
 
6.2.2. Non-transgenic animal model of Alzheimer's disease: Aβ1-42 i.c.v. infusion 
Aβ1-42 peptide was purchased from Abcam (Abcam, Cambridge, UK) and stock 
solutions (1 mg/ml) were prepared in Saline (0.9% NaCl) and stored to − 20 °C. 
Aliquots of Aβ peptides were allowed aggregating by incubation at 37 °C for 72 h 
before in vivo infusion. Rats were anesthetized with a solution of ketamine-xylazine 
(60 + 10 mg/kg, intraperitoneal, i.p.). The skull was positioned in a stereotaxic frame 
(Kopf Instruments, Tujunga, CA, USA), an incision was made along the midline, the 
scalp was retracted and the area surrounding bregma was cleaned and dried. Infusions 
into the left lateral ventricle (coordinates; AP=20.80 mm, ML= +2.0 mm, DV=24.5 mm 
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with respect to bregma) were performed by using 30-gauge injection needles 
connected to 50-µL Hamilton microsyringes by polyethylene (PE-20) tubing. 5 µL of 
Aβ1-42 (1 mg/ml) or its vehicle (saline) were infused at the rate of 1 μL/min by an 
automated syringe pump (KD Scientific, Holliston, MA, USA). The injection needles 
were retained within the target area for 60 seconds following infusion to maximize 
diffusion. 
 
6.3. Drugs injection 
PK2β and PK2 (synthesized by Dr. Rossella Miele) were injected topically into the 
plantar region of mice hindpaws (ipl), in a volume of 20 µl. PK2β and PK2 were diluted 
in sterile saline. 
PC1 was injected subcutaneously (s.c.) into the flank region in a volume of 200 µL/ 
100g body weight. PC1 was dissolved in sterile saline + 0.007% DMSO (dimethyl 
sulfoxide) and administrated at the dose of 150 µg/kg s.c. twice a day, for two weeks 
starting from the day of Aβ1-42 i.c.v. infusion. 
 
6.4. Behavioural tests 
6.4.1. Measurement of thermal nociception 
Thermal hyperalgesia was evaluated using Hot Plate test (Ugo Basile, Verona, Italy). 
Mice were placed on a surface heated to 48°C surrounded by a plexiglass cylinder. The 
latency to various behavioural responses, including jumping, kicking, shaking of foot, 
holding the feet tightly against the body and licking the forepaw, the hind paw or both 
has been used as a measure of pain sensitivity (Hunskaar S. et al., 1986). 
On day of the experiment, the nociceptive threshold to thermal stimuli was measured 
before and at established time points after drug administration. A cut-off time of 15 s 
was assigned prior to the experiments to avoid damage to the animals. 
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The effect of drug was calculated as the percentage change in nociceptive threshold 
from the baseline threshold (% ∆NT) according to the following equation: (% ∆NT) = 
100 x (NTTS – NTB)/ NTB where NTTS is the nociceptive threshold at that time in the 
presence of the test solution and NTB is the baseline nociceptive threshold. 
 
6.4.2. Measurement of tactile allodynia 
Behavioural experiments were carried out in a reserved quiet temperature-controlled 
room. The tactile allodynia was assessed by calibrated Von Frey filaments (2 Biological 
Instruments, Italy). Animals were placed in individual Plexiglas boxes on a raised 
metal mesh surface and allowed to acclimatize for 30-60 min before the test. The 
filaments are manually held, and they can be adjusted according to the paw posture. 
Testing was initiated with a medium-sized filament, which was applied for 3 to 6 s 
until the filament bent slightly. If the animal withdrew the paw, the response was 
considered positive and a filament one size smaller was tried. Conversely, if no 
response was observed, a filament one size larger was tried. The protocol was repeated 
until five changes in behaviour had been observed. The 50% withdrawal threshold was 
determined according to the following equation: Xf+kD where Xf is the value of the 
last von Frey filament used, k is the Dixon value for the positive/negative pattern, and 
D is the logarithmic difference between stimuli (Dixon W. J., 1980). 
 
6.5. Biochemical assay 
6.5.1. RNA extraction and qPCR 
Total RNA was extracted from each sample using the TRIzol® reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer's instructions. RNA yield and purity 
were determined by spectrophotometric absorption at 260 and 280 nm. 1 μg of mRNA 
was used to perform reverse transcription (Reverse Transcriptase, Promega) to obtain 
cDNA. 25 ng of cDNA was amplified by real-time PCR (iCycler; Bio-Rad) by 
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SensiMix™ SYBR (Bioline, Rome, IT) using 0.3 μM of each primer, in a total volume of 
25 µl. All the measures were performed in triplicate. Cycling conditions were: 95°C for 
10 min (for polymerase activation), followed by 40 cycles at 95°C for 15 min, 55±5°C 
(temperature depends on the Tm of the primers) for 15 s and 72°C for 15 s. The reaction 
mixture without cDNA was used as negative control. The Ct (threshold cycle) value of 
the specific gene of interest was normalised to the Ct value of the endogenous control, 
(β-actin or Glyceraldehyde 3-phosphate dehydrogenase, GAPDH), and the 
comparative Ct method (2-ΔΔCt) was then applied using control healthy rats as the 
reference samples.  
The sequences for primer used are:  
β-actin = Forward: 5'-AGATGACCCAGATCATGTTTG-3' Reverse: 5'-
TAGATGGGCACAGTGTGG-3' 
GAPDH = Forward: 5’- TGGCCACCAGTAACATGCAA -3’ Reverse: 5’- 
CTCGATGTCCAGGGCTAGCT -3’ 
PK2 = Forward: 5'-TCATCACCGGGGCTTGCG-3' Reverse: 5'-
TAACTTTCCGAGTCAGGG-3' 
PK2L = Forward: 5'-AGGAAAGAAGAAGGGCGAAG-3' Reverse: 5'-
TCCTTAAACATGCCAAACCTG-3' 
PKR1 = Forward: 5'-CGCACCGTCTCCCTCTAC -3' Reverse: 5'- 
GTTTGACACTTCATCCGCG-3' 
PKR2 = Forward: 5'-CTCCGTCAACTACCTTCGTA -3' Reverse: 5'-
GAGGCGGTCTGGTAATTCA-3' 
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6.5.2. Western Blot assay 
Tissues (whole colon, hippocampus and organotypic cultured of DRG) were 
homogenized in ice-cold lysis buffer (Tris HCl pH 7.5 50 mM, NaCl 150 mM, 
ethylenediaminetetraacetic acid (EDTA) 1 mM and 1% Triton X) or RIPA buffer (Sigma 
Aldrich, St. Louis, MO, USA) containing protease cocktail inhibitors (1% v/v) (Sigma 
Aldrich St. Louis, MO, USA) and centrifuged at 12000 r.p.m. for 10 minutes at 4°C. 
Protein concentrations were determined using the Bradford protein assay. Thirty or 
forty micrograms of protein were resuspended in Laemmli sample buffer (Sigma 
Aldrich St. Louis, MO, USA), boiled for five minutes and separated on 8%, 10 % or 15% 
SDS-polyacrylamide gels.  
After electrophoresis (Bio-Rad, Mini Protean Tetra-Cell, Hercules, CA, USA), the 
proteins were transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA, 
USA) which were blocked for 1 hour at room temperature  with: 1% (w/v) non-fat milk 
and 1% (w/v) bovine serum albumin (BSA) in Tris-buffered saline-Tween 0,1% (TBS-
T) for PK2, PKR1, PKR2, STAT3, pSTAT3 and β-actin (loading control) or 5% w/v no-
fat dry milk powder in TBS-T for GFAP, COX-2 and iNOS or a solution containing 5% 
(w/v) BSA in TBS-T for S100β, Iba-1, p65 and MAP2.  
After blocking, these were incubated overnight at 4°C with one of the primary 
antibodies (Table 3).  
The next day, membranes were broadly washed in TBS-T 0.5%, and then incubated 
with the proper secondary horseradish peroxidase-conjugated antibodies for 1 hour at 
room temperature (for more details refer to the table). 
Immunocomplex were visualized with an enhanced chemiluminescence (ECL) system 
(Amersham, Bucks, UK) and digitized images of immunoreactive bands were acquired 
and the area of each immunoreactive band was measured using the NIH ImageJ 
medical imaging software.  
A ratio of target to loading control were then determined and these values were 
compared for statistical analyses. 
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Primary 
Antibodies  
Company Host 
Blocking 
Solution 
Concentration 
Secondary 
Antibodies 
PK2 Abcam Rabbit 
1%Milk 
1%BSA 
1:500 in Milk 1% 
BSA 1% 
1:2000 in 
1%Milk 1%BSA 
PKR1 
Santa Cruz 
Biotechnology 
Goat 
1%Milk 
1%BSA 
1:500 in Milk 1% 
BSA 1% 
1:8000 in 
1%Milk 1%BSA 
PKR2 
Santa Cruz 
Biotechnology 
Goat 
1%Milk 
1%BSA 
1:500 in Milk 1% 
BSA 1% 
1:8000 in 
1%Milk 1%BSA 
β-Actin Sigma Aldrich Mouse 
1%Milk 
1%BSA 
1:5000 in Milk 1% 
BSA 1% 
1:10000 in 
1%Milk 1%BSA 
GFAP Abcam Rabbit Milk 5% 
1: 50'000 in Milk 
5% 
1: 10000 in Milk 
5% 
S100β Epitomics Rabbit BSA 5% 1: 1000 in BSA 5% 
1:10000 in BSA 
5% 
Iba-1 Abcam Goat BSA 1% 1:1000 BSA 1% 
1:10000 in BSA 
1% 
COX-2 
Cell Signaling 
Technology 
Rabbit Milk 5% 
1: 10'000 in Milk 
5% 
1:10000 in Milk 
5% 
iNOS Sigma Aldrich Rabbit Milk 5% 
1: 9000 in 
BSA 1% 
1:10000 BSA 1% 
p65 
Cell Signaling 
Technology 
Rabbit BSA 5% 
1:2000 in 
BSA 5% 
1:10000 in Milk 
5% 
MAP-2 Novus Biologicals Mouse BSA 5% 1:250 in BSA 5% 
1:10000 in BSA 
5% 
STAT-3 
Cell Signaling 
Technology 
Mouse 
1%Milk 
1%BSA 
1:1000 in Milk 1% 
BSA 1% 
1:2000 in 
1%Milk 1%BSA 
pSTAT3 
Cell Signaling 
Technology 
Mouse 
1%Milk 
1%BSA 
1:1000 in Milk 1% 
BSA 1% 
1:2000 in 
1%Milk 1%BSA 
Table 3. Primary and secondary antibodies and relative WB blocking conditions and buffers. 
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6.5.3. Immunofluorescence assay 
Rats were anaesthetized with mixture of ketamine-xylazine (60 + 10 mg/kg, i.p.) and 
intracardially perfused with a phosphate buffer saline (PBS) solution followed by ice-
cold 4% paraformaldehyde solution in PBS. Brains, were post-fixed for 24 hours, 
transferred in 30% sucrose/PBS solution at 4°C until they sank and coronary sectioned 
using a cryostat (Leica), in 40 μm thick slices. Serial free-floating brain sections were 
incubated at 4°C for 48 hours with the following primary antibodies diluted in PBS-
0.3% Triton X-100: 1/200 rabbit polyclonal anti-PK2 (Abcam, Cambridge, UK), 1/200 
rabbit polyclonal anti-PKR1 and PKR2 (Alomone Labs, Jerusalem, Israel), 1/500 mouse 
monoclonal anti-neuronal nuclei (NeuN), 1/400 mouse polyclonal antiglial fibrillary 
acidic protein (GFAP) (Immunological Sciences, Rome, Italy), 1/200 MAP2 (Novus 
Biologicals, Littleton, CO, USA), 1/200 doublecortin (DCX, Cell Signaling Technology, 
Danvers, USA). After three washes, sections were then incubated for 2 hours at room 
temperature in 1:200 anti-species IgG antibodies coupled to Alexa Fluor®-488 or 555 
(Immunological Sciences, Rome, Italy). Nuclei were stained with DAPI 1/500 (Sigma 
Aldrich). After that, sections were mounted on slides, air dried and coverslipped using 
Fluoromount (Immunological Sciences, Rome, Italy). The stained sections were 
examined by confocal laser scanning microscope (Leica SP5, Leica Microsystems, 
Wetzlar, Germany). Confocal acquisition settings were identical among the different 
experimental cases. For Figure production, brightness and contrast of images were 
adjusted by applying the same values, and by taking care to leave a tissue fluorescence 
background for visual appreciation of the all fluorescence intensity features and to 
help comparison between the different experimental groups. Final Figures were 
assembled by using Adobe Photoshop 7 and Adobe Illustrator 10. Boundaries and 
subdivisions of cortical and hippocampal structures were identified on the base of the 
DAPI histofluorescence using a rat brain atlas (Paxinos). Image acquisitions were 
performed on prefrontal cortex and CA1, CA2, CA3 and Dentate Gyrus (DG) 
hippocampal region. 
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6.6. Statistical Analysis 
Results are expressed as mean ± SEM. When appropriate, one-way ANOVA with 
Tukey’s test for multiple comparisons or two-way repeated measures ANOVA with 
Bonferroni’s post-tests, was performed using GraphPad Prism 5 for Windows version 
5.4. Results are expressed as mean ± SEM. Statistical significance was set at p<0.05. All 
analysis were performed using GraphPad Prism 5 for Windows version 5.4 
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